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ABSTRACT
The PFKFB enzymes control the primary checkpoint in the glycolytic pathway and are
implicated in a multitude of diseases: from cancer, to schizophrenia, to diabetes, and heart
disease. The inducible isoform, PFKFB3, is known to be associated with the upregulation of
glycolysis in many cancers. The first study within this work investigates the potential for using
tier-based approaches of virtual screening to target small molecule kinases, with PFKFB3
serving as a case study. For this investigation, bioactive compounds for PFKFB3 were identified
from a compound library of 1364 compounds via high-throughput screening, with bioactive
compounds being further characterized as either competitive or non-competitive for F6P. Using
the F6P-competitive compounds, several structure based docking programs were assessed
individually and in conjunction with a pharmacophore screening. The results showed that the
tiered virtual screening approach, using pharmacophore screening in addition to structure-based
docking, improved enrichments rates in 80% of cases, reduced CPU costs up to 7-fold, and
lessened variability among different structure-based docking methods.
The second study investigates the structural and kinetic characteristics of citrate inhibition
on the heart PFKFB isoenzyme, PFKFB2. High levels of citrate, an intermediate of the TCA
cycle, signify an abundance of biosynthetic precursors and that additional glucose need not be
degraded for this purpose. Previous studies have noted that citrate acts as an important negative
feed-back mechanism to limit glycolytic activity by inhibiting PFKFB enzymes, yet the
structural and mechanistic details of citrate’s inhibition had not been determined. To study the
molecular basis for citrate inhibition, the three-dimensional structures of the human and bovine
PFKFB2 orthologues were solved, each in complex with citrate. For both cases, citrate primarily
occupied the binding site of Fructose-6-phosphate (F6P), competitively blocking F6P from

vii

binding. Additionally, a carboxy arm of citrate extended into the γ-phosphate binding site of
ATP, sterically and electrostatically blocking the catalytic binding mode for ATP. In the human
orthologue, which utilized AMPPNP as an ATP analogue, conformational changes were
observed in the 2-kinase domain as well as the binding mode for AMPPNP. This study gives
new insights as to how the citrate-mediate negative feedback loop influences glycolytic flux
through PFKFB enzymes.

viii

CHAPTER 1: REVIEW OF LITERATURE
1.1 Glycolysis
The most pressing need of all cells in the body is for an immediate source of energy.
Although ATP can be produced in different ways, virtually all cells possess the capacity to
convert glucose to lactate with the concomitant synthesis of ATP. This conversion, otherwise
known as glycolysis, is the main energy source in many prokaryotes, eukaryotic cells lacking
mitochondria, and eukaryotic cells under low-oxygen conditions (Lodish 2000). In eukaryotes,
the pathway consist of ten cytosolic enzymes that catalyze the steps involved in the oxidation
glucose to pyruvate. Under aerobic conditions, the pyruvate molecules enter the mitochondria
where they are further oxidized to carbon dioxide through the citric acid cycle and the respiratory
chain, ultimately producing up to 36 ATP molecules. Conversely, in anaerobic environments,
pyruvate remains in the cytosol where it is converted to lactate in order to regenerate oxidized
nicotinamide adenine dinucleotide (NAD+), a substrate necessary for additional rounds of
glycolysis. In both circumstances, glycolysis also serves to provide vitally important precursors
for macromolecular synthesis (Fell 1997; Flatt 1995; Fothergill-Gilmore 1987; Mcgilvery 1979).
1.2 The Glycolytic Pathway Is Tightly Controlled
Because all cells require a constant supply of energy to function properly, flux through
the glycolytic pathway must be continuously adjusted in response to fluctuating conditions, both
inside and outside the cell (Metallo and Vander Heiden 2013). The rate by which glucose is
converted to pyruvate is primarily regulated to meet two major cellular needs: (1) maintain
adequate levels of ATP and (2) provision molecular building blocks for macromolecular
synthesis, such as the formation of fatty acids and DNA (Kim et al. 2006; Wegner et al. 2015).
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To ensure these needs are met, glycolysis is subject to stringent regulation at several key steps
(Bertram 2000; DeBerardinis and Thompson 2012).
In mammals, Phosphofructokinase (PFK-1) serves as the most important control point in
the glycolytic pathway, marking glucose’s first point of commitment to the glycolytic pathway.
In this reaction, fructose-6-phosphate (F6P) is phosphorylated at the C1 carbon to form fructose1,6-bisphosphate (F-1,6-P2). Importantly, this reaction serves as the rate-limiting step for the
entire glycolytic pathway and is thus critical in determining glycolytic flux; with increased PFK1 activity resulting in the activation of glycolysis (Banaszak et al. 2011; Dunaway et al. 1988;
Dunaway and Kasten 1988; Evans et al. 1981). Since PFK-1 functions as the central gatekeeper
to the glycolytic pathway, its activity must be tightly controlled. Complex allosteric regulation,
among other regulatory mechanisms, link PFK-1 activity to the energy status of the cell (Furuya
and Uyeda 1980b; Reinhart and Lardy 1980; Yuan et al. 1990). Two indicators of cellular
energy, ATP and AMP, both influence PFK-I activity. High levels of ATP act to inhibit the
enzyme by lowering its affinity for F6P; conversely, AMP acts to reverse this inhibition. This
ATP/AMP ratio provides a mechanism through which the enzymatic activity of PFK-I can be
linked to the energetic status of the cell, preventing unnecessary glucose degradation when
cellular energy levels are adequate (Al Hasawi et al. 2014; Berg 2012; Webb et al. 2015).
Several metabolites from metabolic pathways found downstream of glycolysis also serve
to regulate PFK-1 activity, and thus glycolytic flux. For example, PFK-1 is inhibited by the
phosphoenolpyruvate (PEP) generated in the later stages of glycolysis. In 1980, fructose 2,6bisphosphate (F-2,6-P2) was identified as a potent activator of phosphofructokinase. Fructose
2,6-bisphosphate was found to elevate PFK-1 activity by diminishing the inhibitory effects of
ATP and concomitantly increasing the enzymes affinity for fructose-6-phosphate. By allowing
2

PFK-1 to bypass the inhibitory effect of ATP, F-2,6-P2 acts to uncouple the link between the
cells energy status and the rate of glycolytic flux (Furuya and Uyeda 1980a; Wegner et al. 2015).

Figure 1.1. Fructose-2,6-Bisphosphate, the most potent allosteric activator of glycolysis. (A)
Reciprocal regulation of the glycolytic and gluconeogenic pathways by F-2,6-P2. (B) The
chemical structure of fructose-2,6-bisphosphate. (C) Initial velocity curve showing the effects of
varying concentrations of F-2,6-P2 on ATP inhibition.
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1.3 The Bifunctional Enzyme, PFKFB
As previously noted, the concentration of F-2,6-P2 significantly influences the overall rate
of glycolysis via allosteric activation of the rate-limiting enzyme, PFK-1. The intracellular
concentration of F-2,6-P2 is controlled by a family of bifunctional 6-phosphofructo-2kinase/fructose-2,6-bisphosphatases (PFKFB) that are encoded by four, tissue-specific, genes
(O. Minchenko et al. 2003). Although different in size, kinetics, and regulatory properties, each
of the four isoforms has kinase and phosphatase activities, allowing for both the synthesis and
degradation of F-2,6-P2. Thus cellular levels of F-2,6-P2 are determined by a balance between its
production and consumption, which are handled two clearly divided functional domains (Leipe
et al. 2002; Leipe et al. 2003; Rigden 2008).
Each PFKFB monomer consists of a single polypeptide chain that can be subdivided into
four distinct regions: the 6-phosphofructo-2-kinase (6-PF-2-K) domain, the fructose-2,6bisphosphatase (F-2,6-P2ase) domain, and two regulatory domains. The two catalytic domains
are conserved among the different tissue isoforms with the sequence identity for both domains
being >85%. These two domains are connected by a partially flexible linker region that allows
for small rotational deviations among isoforms, possibly influencing binding kinetics and/or
catalytic rates. Flanking the functional N-terminal and C-terminal domains are two regulatory
domains. Unlike the catalytic domains, little sequence similarity is shared among the regulatory
domains of the four isoforms. Studies have demonstrated these domains to have very distinct
posttranslational modification profiles (Cavalier et al. 2012; Hasemann et al. 1996; Kim et al.
2006; Y. H. Lee et al. 2003).

4

A.

B.

(GTPase-like)

(PGM-like)

Figure 1.2. Structure of human PFKFB3. (A) Structure of the human PFKFB3 functional
homodimer in a head‐to‐head conformation. Likewise, PFKFB1 and PFKFB4 are also
functional homodimers with the same head‐to‐head arrangement. (B) Ribbon diagrams
are used to represent the two catalytic domains of the bifunctional enzyme.
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The N-terminal half of the polypeptide forms the kinase domain, which is responsible for
the ATP-dependent phosphorylation of F6P to form F-2,6-P2. The domain consist of a six
stranded, predominantly-parallel β-sheet neighbored by seven α-helices. Forming the active site,
are the Walker A (GXXXGKT/S) and B (ZZZZD, with Z being any hydrophobic residue)
motifs, which facilitate ATP binding as well as the octahedral Mg2+ ion coordination between the
protein and the β- γ- phosphates of ATP (Hasemann et al. 1996; Ramakrishnan et al. 2002;
Walker et al. 1982). Together, these motifs resemble the P-loop NTPase domain of adenylate
kinase (Leipe et al. 2003).
For catalysis, the two substrates, ATP and F6P, are positioned and oriented such that a
strong, direct, substrate-substrate interaction is achieved between the O2 oxygen of F6P and the
γ-phosphate of ATP (Kim et al. 2007). Upon the substrate-assisted deprotonation of the O2
oxygen, F6P can perform a nucleophilic attack on the γ-phosphate of ATP. This is followed by
an “in-line” transfer of phosphate accompanied with the inversion of the phosphate
stereochemistry (Kim et al. 2007; Kitajima et al. 1984; Klahn et al. 2006; Lahiri et al. 2003;
Wittinghofer 2006).
Conversely, the C-terminal half of the polypeptide forms the bisphosphatase domain,
which catalytically-opposes the reaction performed by the kinase domain. Structurally, the
domain is globular, much like the kinase domain, and contains a six-stranded, predominantlyparallel β-sheet neighbored by several α-helices (Furuya et al. 1982; Van Schaftingen and Hers
1981). Overall, the F-2,6-P2ase domain is homologous with the phosphoglycerate mutase family
of enzymes (Bodansky 1972; Fothergill-Gilmore and Watson 1989).

6

Figure 1.3. P-loop NTPase. Typical binding of a nucleotide triphosphate by the Walker A and B
motifs of a P-loop NTPase fold. (Cavalier et al. 2012)

7

Figure 1.4. Substrate binding and mechanism. (A) Direct substrate/substrate interactions
generated from the pseudo-Michaelis complex using AMPPCP and F6P. (B) In-line positioning
of the bridge oxygen, γ-Phosphate, and 2-O of F-6-P. (C) Reaction Mechanism of PFKFB3 6PF-2Kase domain. (D) Ordered Sequential Reaction of the 6-PF-2Kase domain.
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In vertebrates, four tissue-specific PFKFB isoforms, encoded by four distinct genes, act
to tightly regulate levels of glycolytic flux within particular tissues: liver (PFKFB1), heart
(PFKFB2), inducible (PFKFB3), and testis (PFKFB4). Despite having highly similar kinase and
bisphosphatase catalytic cores, isoforms differ among their kinase and phosphatase activities,
tissue distributions, and its regulatory response to post-translational modifications (O.
Minchenko et al. 2003; Pilkis et al. 1995).
1.3.1 Liver Isoform (PFKFB1)
The PFKFB1 gene, which codes for the liver isoform, contains 17 exons encoding three
alternatively spliced transcript variants (L, M and F) that differ only within their first exon. The
12 consecutive exons (2-13) shared among all three variants correspond to the kinase and
phosphatase catalytic cores, with each being encoded by six exons (Algaier and Uyeda 1988;
Lange and Pilkis 1990; Taniyama et al. 1988). The first exon of the L isoform encodes 32 amino
acids and gives rise to largest splice variant, which notably contains a phosphorylatable Ser32
residue (El-Maghrabi et al. 1982a; El-Maghrabi et al. 1982b). This splice variant is expressed
mainly in the liver, but is also found in the skeletal muscle and white adipose tissue. In contrast
with the L isoform, the first exon for the M variant only codes for 9 unrelated amino acids that
are devoid of a phosphorylation site. The M isoform is predominantly expressed in the skeletal
muscle and white adipose tissue. The F mRNAs, on the other hand, are very similar to the Misoform, the only difference being a truncation of the first exon. Additionally, expression for the
F variant is predominant in fibroblasts and fetal tissue (Rider et al. 2004; Ros and Schulze 2013).
Unlike the M and F variants, the L variant is subject to regulatory control via
phosphorylation at the N-terminus (Y. H. Lee et al. 2003). Such regulation is observed in
response to glucagon, which stimulates a cAMP-dependent protein kinase to phosphorylate an L
9

variant-specific Ser32 (Murray et al. 1984). The result of phosphorylation is an inactivation of 6PF-2-K activity with a concomitant increase of F-2,6-P2ase activity, shifting the kinase-tophosphatase activity ratio from 1.4 to 0.2 (El-Maghrabi et al. 2001). However, because the M
and F splice variants lack an N-terminal phosphorylation site, their catalytic actities are not
subject PKA mediated regulation. The rationale underlying the differential regulation between
splice variants can be understood when comparing liver and muscles isoforms. Because the liver
primarily responsible for controlling blood glucose levels, it is imperative that glycolytic flux be
regulated so that glucose can be stored when plentiful and released when scares. Muscles, on the
other hand, are not responsible for controlling blood glucose levels, reducing the need for such
regulation (Darville et al. 1992; Dupriez et al. 1993).
1.3.2 Heart Isoform (PFKFB2)
The PFKFB2 gene, which codes for the heart isoform, contains 15 exons encoding two
alternatively spliced transcript variants. The proteins differ at the C-terminal due to an
alternative splicing deletion of exon 15, giving rise to a truncated (54 kDa) and full-length (58
kDa) variant. The removal of exon 15, which is responsible for encoding a C-terminal sequence
containing several phosphorylation sites, is associated with a loss of regulatory control. For the
full length protein, phosphorylation at the C-terminus by PKA is associated with an increase
kinase activity and a decrease in bisphosphatase activity, which is in direct opposition to the
regulatory effects experienced by PFKFB1 upon phosphorylation (Chikri and Rousseau 1995;
Heine-Suner et al. 1998; Ros and Schulze 2013).
As for the overall structure, PFKFB2 shares a highly conserved catalytic core with the
liver isoform. The N-terminus of PFKFB2, on the other hand, lacks phosphorylation sites,
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making the C-terminus responsible for all regulatory control of the enzyme. (Deprez et al. 1997;
Ros and Schulze 2013).
1.3.3 Inducible Isoform (PFKFB3)
PFKFB3, the gene product of pfkfb3, has termed the brain/placental PFK-2, inducible
PFK-2 (iPFK-2), and ubiquitous PFK-2 (uPFK-2) due to its ubiquitous expression among
tissues. More recently, PFKFB3 has also been referred to as the ‘cancer isoform’ due to its
overexpression and persistent, regulatory activation within numerous tumor cell lines (Kessler
and Eschrich 2001; Manzano et al. 1998; Navarro-Sabate et al. 2001). Among the four isoforms,
PFKFB3 has been demonstrated to have the highest kinase/phosphatase activity ratio and is thus
associated with elevated F-2,6-P2 levels in tissues where it is expressed. In fact, the
bisphosphatase domain of PFKFB3 is almost inactive, making its contribution to F-2,6-P2 levels
negligible when considering the overwhelming high kinase activity of the enzyme (Sakakibara et
al. 1999). The 2006 crystal structure of PFKFB3 shed light on the enzyme’s unusually high
kinase activity as well as its abnormally low bisphosphatase activity (Kim et al. 2006). The
structure revealed an N-terminal, β-hairpin motif that makes contact with residues of the
bisphosphatase catalytic site, possibly inhibiting F-2,6-P2ase activity. Moreover, the structure
also revealed that the sequence of PFKFB3’s kinase domain, as compared with other isoforms,
has decreased conformational flexibility in regions near the ATP and F6P substrate loops, likely
resulting in enhanced substrate binding (Kim et al. 2006).
PFKFB3 expression is stimulated by hypoxia through the activation of the HIF-1
transcription factor. In addition, certain oncogenes, such as c-myc, c-ras, and c-src, have been
shown to exert complementary effects on PFKFB3 expression as well as cell proliferation
(Chesney et al. 1999; Chesney et al. 2005). Regulatory activation, on the other hand, involves
11

phosphorylation of a C-terminal Ser461 by PKA, PKB, PKC, or AMPPK. Such phosphorylation
serves to elevate PFKFB3’s kinase-to-bisphosphatase activity ratio from 700:1 to 2400:1,
resulting in dramatic increases in glycolytic flux (Ros and Schulze 2013; Sakakibara et al. 1997).
Studies have found that in many cancers, PFKFB3 is both highly expressed and highly
phosphorylated, suggesting that PFKFB3 is strongly linked to the elevated glycolytic activity
within cancer cells (Dihazi et al. 2003; Lewis et al. 1997; Shim et al. 1998; Telang et al. 2006)
1.3.4 Testis Isoform (PFKFB4)
The testis isoform of PFKFB, the gene product of pfkfb4, shares a highly conserved
catalytic core and C-terminus with the liver isoform. However, unlike other isoforms, PFKFB4 is
not subject to regulation by phosphorylation as it is devoid of phosphorylation sites on both Nand C-termini (Sakata et al. 1991). Testis tissues are known to have persistently high glycolytic
activity which is in line with the enzyme’s kinetic profile. Compared to the liver isoform, the 2Kase:2-Pase activity ratio is approximately three times higher for the testis isoform. Moreover,
because glycolytic activity is persistently high within testis tissues, regulatory control of the
enzyme is not needed, explaining the lack of phosphorylation sites (Manzano et al. 1999; Rider
et al. 2004; Ros and Schulze 2013).
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Figure 1.5. Summary of Phosphorylation Sites and Enzyme Kinetics of PFKFB
Isoforms. (A) Schematic showing the empirically known phosphorylation sites of each
tissue-specific isoform of PFKFB. (B) Table containing the kinetic properties of each
PFKFB isoform.

1.4 Glycolytic Modification in Cancer Cells: The Warburg Effect
While normal cells generate a majority of their energy and biosynthetic precursors
through a combination of glycolytic and oxidative metabolism, cancer cells dramatically
reprogram their metabolism to strongly favor aerobic glycolysis (R. G. Jones and Thompson
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2009; Yeluri et al. 2009). Numerous studies have demonstrated that glycolytic rates in rapidlygrowing tumor cells can be up to 200 fold higher than those of their normal tissues counterparts,
even in the presence of abundant oxygen. Typically, however, cancer cells in rapid growth
phases experience hypoxia ─ an insufficient supply of oxygen ─ and have limited nutrient
exchanges with neighboring cells (Bertram 2000; Kim et al. 2006; Pelicano et al. 2006). To
survive under such harsh conditions, cancer cells must reprogram their metabolic pathways to be
less dependent on oxygen availability and interactions with neighboring cells (Gatenby and
Gillies 2004; Moreno-Sanchez et al. 2007). This altered metabolism results from oncogene
activation and/or the loss of tumor suppressor genes in multiple signaling pathways.
High levels of glycolytic metabolism confer several competitive advantages to cancer
cells. Firstly, although glycolysis yields less ATP than oxidative phosphorylation (OXPHOS),
the speed at which energy can be produced is much higher from aerobic glycolysis.
Additionally, because cancer cells are less reliant on mitochondrial OXPHOS for energy, fewer
reactive oxygen species (ROS) are generated, which are cytotoxic to both normal and cancer
cells (Bui and Thompson 2006; Holley et al. 2012). Secondly, increased glycolytic flux provides
precursors necessary for the biosynthesis of nucleotides, lipids, and many other metabolites that
are essential for survival and proliferation. Thirdly, besides providing cells with ample energy
and biosynthetic building blocks, cancer cells suppress the growth of healthy neighboring cells
by altering the nearby microenvironments (Pfeiffer et al. 2001). One way they do this is through
consuming the majority of diffusible substrates, leaving little for normal cells. A second is
through lowering extracellular pH levels, which are established by enhanced lactate production,
promoting apoptosis of neighboring normal cells while enhancing invasion and metastasis
characteristics of cancer cells (Gatenby and Gillies 2004).
14

Enhanced glycolysis observed in cancer cells is, at least, partially attributed to an
impairment of mitochondrial function, including decreased expression of certain mitochondrial
transporters and oxidative enzymes, a truncated TCA cycle, fewer mitochondria per cell, a
defective electron-transport chain, higher levels of natural inhibitors for the mitochondrial ATP
synthase, and increased sensitivity of mitochondrial DNA to oxidative stress (Bertram et al. 2001
(Bertram 2000; DeBerardinis and Thompson 2012; Xu et al. 2005). Studies have demonstrated
that oncogenes such as c-ras, c-src, and c-myc upregulate the majority of glycolytic enzymes,
including PFKFB3, hexokinase-2, and lactate dehydrogenase (Levine and Puzio-Kuter 2010).
Additionally, the activation of hypoxia-inducible factor-1 (HIF-1) plays a fundamental role in
promoting glycolysis in cancer cells. Although HIF-1 is present in normal cells, it is
continuously degraded under aerobic conditions. In cancer cells HIF-1α, a regulatory subunit of
HIF-1, is overexpressed and, in addition, stabilized by hypoxic tumor microenvironment,
resulting in the upregulation of most glycolytic enzymes (Brahimi-Horn and Pouyssegur 2006;
Caro 2001; Ke and Costa 2006). This phenomenon of enhanced glycolysis in cancer cells has
been termed the Warburg effect (Warburg 1956).
1.5 PFKFB and Cancer Metabolism
In most eukaryotic cells, PFK-1 experiences strong inhibition from cellular
concentrations of ATP under physiological conditions; such inhibition often plays a pivotal role
in allowing cells to respond to nutritional and hormonal signals at the levels of transcription,
translation, and post-translational modification (Ros and Schulze 2013). Cancer cells, on the
other hand, frequently bypass this regulatory mechanism by increasing cellular concentrations of
F-2,6-P2 (Yalcin et al. 2009). Numerous studies have demonstrated that the steady-state
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concentration of F-2,6-P2 is much higher among cancer cell lines and is frequently associated
with elevated rates of proliferation, cell-cycle progression, and transformation (Clem et al. 2008).

Figure 1.6. Overview of the Metabolic Reprogramming of Tumor Cells. Diagram showing the
molecular mechanisms responsible for the Warburg Phenotype.

The inducible PFKFB3 is the predominant isoform in most neoplastic cells including
cancer (Chesney et al. 1999; Navarro-Sabate et al. 2001). Unlike the other isoforms, PFKFB3 is
ubiquitously expressed in almost all cells via the actions of c-Myc, the downstream transcription
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activator of RAS and various growth factors, or the hypoxia-inducible factor 1 upon the onset of
hypoxia, a condition common to most fast growing cell populations (Dang and Semenza 1999;
A. Minchenko et al. 2002; Mor et al. 2011; Obach et al. 2004). With its exceptionally high 2Kase activity and low 2-Pase activity, PFKFB3 can maintain F-2,6-P2 levels over 10-fold higher
than other isoforms, providing a clue to the mechanism underlying vigorous glycolysis of cancer,
long known as the ‘Warburg effect’ (Pilkis et al. 1995; Warburg 1956). As such, expression of
PFKFB3 is suppressed by p53 and, moreover, in the presence of p53, TiGAR (p53-inducible
regulator of glycolysis and apoptosis regulator) down-regulates the cellular F-2,6-P2 level, to
suppress tumorigenic transformation and proliferation (Green and Chipuk 2006; Maddocks et al.
2013; A. Minchenko et al. 2002; O. Minchenko et al. 2003). Moreover, studies have shown that
the overexpression of PFKFB3 in several cancer cell lines occurs through a HIF-1 dependent
mechanism. Furthermore, it was found that suppression of PFKFB3 via gene silencing resulted
in a reduction of cellular F-2,6-P2 and depressed glycolytic flux, reducing cancer cell viability
(Calvo et al. 2006). Since PFKFB3 is the dominant form in most cancer cells, it is an emerging
target of cancer chemotherapy.
1.6 PFKFB as a Chemotherapeutic Target
The importance of F-2,6-P2 to cancer’s altered metabolism has made the bifunctional enzyme a
popular target for development of anti-neoplastic agents and diagnostic procedures (Ros and
Schulze 2013). One such example is a molecular imaging technique known as positron emission
tomography (PET), which uses a glucose analog probe, 2-deoxy-2-[18F]fluoro- D-glucose
(FDG), to explore the possibility of cancer metastasis on the basis of high glucose consumption
associated with the presence of solid tumors (Maddocks et al. 2013; Wechalekar et al. 2005).
With regard to anti-neoplastic agents, the dependency of cancer cells on enhanced glycolysis for
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energy production, in combination with the suppression of mitochondrial OXPHOS to prevent
harmful ROS accumulation, gives rise to several potential targets for therapeutic intervention.

A.

B.

Glucose

FDG
Figure 1.7. Exploiting the Warburg Effect using Positron Emission Tomography (PET). (A)
Glucose and the glucose analogue probe FDG (2-deoxy-2-[18F]fluoro- D-glucose ). (B) FDGPET/CT taken at several timepoints during chemotherapy treatment. (Lagaru et al. 2009)

Because PFKFB3 displays the highest 2-Kase:2-Pase activity ratio, it is hypothesized that
PFKFB3 may prove to be an attractive target to cancer therapy (Atsumi et al. 2002; Atsumi et al.
2005; Mor et al. 2011). Studies have shown that gene silencing studies involving PFKFB3
results in a reduction of glycolysis and suppression of cancer cell viability and growth,
supporting the assumption of PFKFB3 being a promising target for cancer chemotherapeutics.
Below, the most promising drug candidates for PFKFB3, and the current stage of each, are
briefly described.
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3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) was developed based on the structure
derived from another isoform, PFKFB4. It blocks fructose-6-phosphate from entering the active
site of the kinase domain. In vivo studies on neoplastic cells have confirmed that 3PO does
suppress glycolysis. Moreover, in studies with melanoma cell lines, it was quantitatively
determined that the concentrations of Fru-2, 6-P2, ATP, lactate, NAD+, and NADH are reduced
upon 3PO introduction. The isoform selectivity of 3PO is not yet known (Clem et al. 2008).
N4A and N4A Derivatives
Compared to 3PO, N4A (5,6,7,8-tetrahydroxy-2-(4-hydroxyphenyl)chromen-4-one) is a
PFKFB3 inhibitor based on the crystal structure of PFKFB3. Its derivatives are suggested to be
improved from the subsequent structure-guided optimization. They bind to the F-6-P pocket of
PFKFB3 and inhibit its F-2,6-P2 synthesis, leading to low glycolysis and, ultimately, death of
cultured cancer cells with no random toxicity. N4A and its derivatives are functionally selective
to PFKFB3 and have been shown to induce death of cultured HeLa and T47D cancer cells by
efficiently blocking glycolysis (Seo et al. 2011).
PFK-158
PFK158 is a derivative of 3-(3-pyridinyl)-1-[4-pyridinyl]-2-propen-1-one (3PO) that exhibits
better potency and pharmacokinetic properties than the parent molecule. PFK-158 was
discovered and developed by Advanced Cancer Therapeutics (ACT) and is currently undergoing
Phase I clinical trials. Mouse model studies demonstrated ~80% growth inhibition with
advanced solid malignancies, with comparable dosages being well tolerated in both rats and
dogs. This molecule represents the first-in-man and first-in-class inhibitor for PFKFB3 that
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prevents tumor cells from using glucose as a fuel source for survival, growth and metastasis
(Chesney et al. 2015; Natarajan et al. 2011).
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CHAPTER 2: REVIEW OF LITERATURE
2.1 Drug Discovery and Development
The process of discovering and developing novel therapeutics is complex, expensive,
and time-consuming (Dickson and Gagnon 2004b, 2004a; DiMasi et al. 2003). According to a
report published in 2014 by the Tufts Center for the Study of Drug Development (CSDD), the
cost of developing a prescription drug that gains market approval is approximately $2.6 billion, a
145% increase, correcting for inflation, over the estimates from 2003 (Hughes et al. 2011; Kaitin
2015). However, despite a two-fold increase in production costs, the time associated with
bringing a drug to market has remained stagnant, with each new drug taking on average 12-15
years to develop. Furthermore, despite increasing financial investments in pharmaceutical R&D,
there has been a steep rise in the attrition rate of drug candidates (C. P. Adams and Brantner
2010; Mahajan and Gupta 2010a, 2010b). This is currently one of the most significant
challenges facing pharmaceutical industry as a whole. An overview of the drug development
pipeline, from discovery to market approval is shown in figure 2.1.

Figure 2.1. Standard Drug Development Pipeline. Model showing the distinct phases of drug
discovery and development as well as the associated time and cost.
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Initially, there must be a disease or symptom for which there is a need for a novel drug.
The first step in the actual discovery process is target identification and validation, which
typically occurs via basic research on molecular pathways (Hughes et al. 2011). Once a potential
target has been selected, a cell-based assay must be designed so that the biological activity of the
compounds can be tested (S. Fox et al. 2006; M. P. Fox and Fox 2006; Moore and Rees 2001).
In the lead discovery phase, compounds which modulate the biological activity of the drug target
are identified through the screening of large compound collections in vitro. Subsequently in lead
optimization, the most promising leads are subjected to several rounds of chemical modification
to improve potency and pharmacokinetics properties of each compound. Next, the most
bioactive compounds generated from lead optimization are tested for efficacy and toxicity in the
preclinical development stage using animal models (Hughes et al. 2011). On average, only 1 of
every 50 compounds from the pre-clinical phase is tested in human clinical trials, and of these
compounds, only 1 of 5 compounds gets registered by the FDA (Hay et al. 2014). Because of
the logarithmic nature of compound elimination during drug development, the costs steeply rise
after each stage in the process (Lloyd and McElwee 2011). It is therefore of vital importance to
drug developers to keep failure rates as low as possible during the later stages of development.
Traditionally, this is done by simultaneously testing several protein targets against huge chemical
libraries to select the best protein and lead compound set . More recently, drug developers have
found that a less expensive solution is to use computational techniques to prioritize drug targets
and lead candidates to maximize the likelihood of developing a successful drug.
2.2 Virtual Screening
Over the past two decades, high-throughput screening (HTS) has been the standard
method for the identifying new, bioactive compounds. However, because of the complex,
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expensive, and time-consuming nature of HTS, computational screening, otherwise known as
virtual screening (VS) has become increasingly popular in pharmaceutical research. In essence,
virtual screening and high-throughput screening have the same goal (i.e. the identification of
novel bioactive compounds (HITs)), yet operate using different philosophies. Whereas HTS
aims to experimentally test increasingly large numbers of compounds in the most efficient
manner, virtual screening deviates from this ‘screen everything’ paradigm and attempts to
rationalize compound selection strategy to reduce the number of candidates for experimental
evaluation and promote the prioritization of physical resources to ‘high-potential’ candidates
(Braga et al. 2014; Cheeseright et al. 2011; Ripphausen et al. 2011). Despite the critical role of
HTS in the early stages of drug discovery, the many technical advances, and the tremendous
improvements in HTS capacity, VS has still become an established discipline in pharmaceutical
research (Bajorath 2002; Kitchen et al. 2004; Macarron 2006; Macarron et al. 2011; Macarron
and Luengo 2011).
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Virtual screening consist of a spectrum of computation methods designed to efficiently
search large chemical libraries in silico for compounds likely to be active for a biological target
of interest. The efficiency of this technique depends on both performance of the screening
methods and the content of the database to be screened (Polishchuk et al. 2013). Traditionally,
the practice consisted of searching a company’s propriety database of compounds comprising the
structures of millions of real molecules from a corporate collection (Cheeseright et al. 2011).
Over time, as methods have improved, so too has the size of the chemical database that can be
feasibly screened. Virtual screening is now being used to screen hundreds of millions of virtual
compounds, created from enumerating combinatorial libraries in chemical space (Boehm 2011;
X. H. Ma et al. 2012b). HTS, however, can only test compounds that are physically acquirable.
Herein lies a tremendous advantage unique to virtual screening. As of 2013, an ensemble of
academic, commercial and propriety databases record approximately 60 million structures of
existing chemical compounds. Chemical space, on the other hand, which represents all possible
(i.e. energetically stable) chemical compounds is estimated to be ~1033, making the number of
compounds known to exist less than 1 in 6×1024 of those that presumed possible (Polishchuk et
al. 2013; Reymond and Awale 2012). Virtual screening methods are largely into two
approaches, ones that take the 3D structure of the target protein into account (structure-based
drug design, SBDD), and ones that rely on information derived from one or more known
bioactive molecules (ligand-based virtual screening, LBVS). Generally speaking, SBDD aims to
identify bioactive small molecules from ‘docking’ them into a binding site of a target protein
(Kitchen et al. 2004; Lyne 2002). LBVS, on the other hand, uses physicochemical properties
from one or more known bioactive molecules to identify novel structures with the desired
bioactivity (Eckert and Bajorath 2007). Such methods are not mutually exclusive, and given
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Figure 2.3. Approaches to Virtual Screening. Shown are the two main categories of virtual
screening: structure-based and ligand-based.

the prerequisites of each, can be used in concert (D. L. Ma et al. 2012a; Peltason 2008). The two
principal types of virtual screening are discussed below.
2.3 Docking-Based Approaches
Molecular docking can broadly be defined as a computational tool ─ belonging to the
field of structure-based drug design ─ that attempts to exploit the enzymatic concepts of lockand-key and/or induced fit binding models to provide useful predictions about potential ligandprotein (or RNA) interactions (Berg 2012; Blaney 2012; Hughes et al. 2011; Yuriev et al. 2011).
Since its beginnings in the early 1980’s, docking, along with tremendous developments in
chemistry, physics, informational technology, biochemistry, and computer technology, has
become an essential tool in drug discovery (Chen 2015; Ferreira et al. 2015). Initially, docking
studies served primarily as a means to predict binding poses and estimate approximate binding
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affinities between protein-ligand complexes from scoring interaction energies (Ferreira et al.
2015). Early successes in binding pose predictions set the groundwork for future development
on docking programs and led to the exploration of docking as a tool to identify HITs during the
early stages of drug discovery (Brooijmans and Kuntz 2003; Krumrine et al. 2003). Now,
docking is considered an essential tool for lead discovery and is associated with a myriad of
success stories and FDA approved drugs (Millan 2012).

Figure 2.4. Classification of methods for protein-ligand docking.
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In molecular docking, the 3-demensional shape of a binding site is used to optimize the
ligand’s position and orientation to best fit the receptor. In biological systems, the driving force
facilitating such interactions arises from complementarities in both shape and electrostatics of the
ligand to the binding site surface (Bikker et al. 2009; Halperin et al. 2002). In addition to
coulombic interactions such as hydrogen bonds, salt bridges, π-cation, and π-π interactions,
hydrophobic forces such as Van der Waals interactions also contribute to binding affinity
(Bikker et al. 2009; Landry and Gies 2008). In reality, such interactions are best described by
quantum mechanics; however, due to the complexity of biological systems, quantum theory
cannot be applied directly (Gao et al. 2002; Goodwin et al. 2002).
Molecular docking can be divided into two separate problems: sampling and scoring.
Sampling refers to the generation of putative ligand binding conformations/orientations near a
binding-site of a target receptor and can be subdivided into two facets, ligand sampling and
protein flexibility (Bikker et al. 2009; Ferreira et al. 2015; Krumrine et al. 2003). Scoring, on the
other hand, refers to the evaluation of binding tightness of an individual ligand for a particular
receptor using either physical or empirical energy scoring functions. During a docking
campaign, sampling and scoring processes are carried out recursively for each ligand until
convergence at a minimum energy conformation. The top binding pose, namely the one with the
lowest fitness score, is predicted to be the binding mode for the compound (Danishuddin and
Khan 2015; Halperin et al. 2002). Predictions of absolute binding free energies, however,
remains a significant limitation of docking methods due to simplifications and approximations
made to reduce computational demands. Below we will examine each of the major stages.
Additionally, the importance, potential, and drawbacks of side chain and backbone flexibility in
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structure based docking will also be briefly explored (Cavasotto and Orry 2007; Gane and Dean
2000; Huang et al. 2010; Orry et al. 2006).
2.3.1 Protein Flexibility
Until recently, docking algorithms exhibited little or no flexibility of molecules in the
active site, typically treating proteins as completely rigid structures. However, the basic
assumption made by these programs, in that proteins are rigid molecules, is a serious limitation
because induced fit and conformational flexibility are often critical factors in complex formation
(B-Rao et al. 2009; Durrant and McCammon 2010). This is problematic since the process of
docking uses crystal-structures and/or homology models, which are only a single representation
of one of the many potential protein conformations found in solution. Hence, adjustments to
flexible side chains in the binding site are often necessary for proper ligand binding, which is
underscored by the results from “cross-docking” experiments (Bissantz et al. 2000; Warren et al.
2006). In cross-docking tests, a flexible ligand is docked into a receptor crystal structure that
was crystallized with another ligand bound. From experiments using cross-docking, it was
shown that success rates in reproducing the known bound conformation of the ligand is
significantly lower in cross-docking experiments than in regular docking experiments (Durrant
and McCammon 2010).
Although the existence of ligand-induced flexibility was reported in scientific journals
nearly 50 years ago, for a very long time, it was generally considered to be rare or
inconsequential. However, recent statistical studies of the Protein Data Bank revealed that
nearly 85% of all known proteins contain between one and three flexible residues in the active
site. Additionally, another study reported that rigid receptor dockings predictions are incorrect in
predicting the binding pose in 40–60% of all studied cases (B-Rao et al. 2009). Many factors
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have hindered the development of methods for dealing with ligand-induced protein
conformational changes. Among these is a lack of a clear understanding of what kinds of
changes may be induced by a ligand in a given protein. Additionally, the numerous degrees of
freedom involved in incorporating protein flexibility during docking have posed computational
challenges (Barril and Fradera 2006a; Carlson 2002b, 2002a; Sotriffer 2015).
Dealing with protein flexibility is a multi-variable problem that entails everything from
side-chain movement, to backbone-loop movements, to major domain rearrangements (Halperin
et al. 2002). The earliest attempts to mimic small amounts of protein flexibility applied soft
potentials to rigid receptors to allow for some overlap toleration between the ligand and the
protein (Lexa and Carlson 2012; May and Zacharias 2005). Such soft scoring functions allowed
for some plasticity of the receptor but are limited in their scope to small levels of protein
flexibility. Although limited in their potential for simulating true flexibility, soft docking
methods are computationally efficient and are still being actively used (Mangoni et al. 1999).
Survey methods are a more recent alternative to modeling protein flexibility. They come
in a variety of implementations, but in general, they are similar in principle to the approach of
exploring multiple ligand conformations for simulating ligand flexibility (Barril and Fradera
2006b; Corbeil and Moitessier 2009; Corbeil et al. 2009). One type of survey method for
modeling protein flexibility deals with the incorporation of rotamer libraries to simulate sidechain flexibility (Koveal et al. 2013). However, since this model can’t handle backbone changes,
it fails to fully simulate ligand-induced flexibility (McGovern et al. 2002). Another survey
method attempts to simulate flexibility by using ensembles of rigid-receptors. Studies on the use
of ensembles to simulate protein flexibility have generally found that ensemble-based methods
are more accurate in ranking scores, yet are computationally more expensive and also require
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multiple high-resolution crystal structures (B-Rao et al. 2009). The last major survey method
used to represent protein flexibility incorporates molecular dynamic simulations to simulate both
backbone and side chain movement. In this method, induced fit is able to be accounted for as
well as explicit solvents and ionic effects. The drawback to MD based survey methods resides in
the extremely high computational costs, which are impractical for high-throughput screening
jobs even when using computing clusters (Cosconati et al. 2012; Fischer et al. 2014).
Because of the complications associated with protein flexibility, we have only recently
attained the requisite computational resources for flexible docking to be considered a feasible
approach for high-throughput screening (Huang et al. 2010). However, despite having now
acquired the computational means for flexible docking, that is not to say that the problem is
solved. The jump from rigid to flexible/semi-flexible receptors is just problem of computational
resources, but also of complexity (Fischer et al. 2014). By allowing for receptor flexibility, there
are enormous increases in the degrees of freedom in the binding calculations; which is taking a
complex system and adding additional complexity. However, despite the difficulties, the
potential exist for dramatic improvements in binding predictions from incorporating flexibility.
By increasing the variables in the system, we are better able to mimic real-world systems, which
should ultimately allow for binding predictions to more closely correlate to reality (Huang et al.
2010; Sotriffer 2015).
2.3.2 Search Algorithms
Docking algorithms generally consist of two separate search engines; one for the
placement of a ligand within the receptor’s binding site and the other for sampling the ligand’s
internal degrees of freedom that arise from rotational bonds, stereoisomers, and alternative ring
conformations (Bikker et al. 2009; Dias et al. 2008a; Dias and de Azevedo 2008; Yuriev et al.
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2011). The first process, refers to the orientation algorithms, which describe the surface of the
protein using mathematical models. Generally this class of algorithms can be divided into three
categories: grid search, descriptor matching, and energy-based searches. The second process,
termed ligand sampling, is responsible for dealing with the flexibility of ligands and can be
divided into two categories: systematic searches and stochastic searches (Ferreira et al. 2015;
Halperin et al. 2002).
2.3.2.1 Ligand Orientation Algorithms
GRID-BASED

Grid-based searches are a class of orientation algorithms that exhaustively

search the binding site by moving a rigid ligand through the six translational degrees of freedom
associated with three-dimensional space in a systematic, stepwise fashion (Ferreira et al. 2015;
Halperin et al. 2002; G. S. Wu et al. 2003) For this method, performance and accuracy are
directly correlated with the size of the search grid and the step increments. Traditionally, such
methods were developed to search through Cartesian space; however, more recent methods
typically favor the use of Fourier space as a means to reduce search times (Brooijmans and
Kuntz 2003; Millan 2012; G. S. Wu et al. 2003). However, due to the large number of degrees
of freedom associated with the flexibility of ligands, this method is typically used for proteinprotein docking where both molecules are treated as rigid bodies (Cai et al. 2002; Danishuddin
and Khan 2015; Millan 2012; Yuriev and Ramsland 2013).
DESCRIPTOR MATCHING

Descriptor matching searches that aim to be more efficient

than grid-based approaches by representing the active site as a spacial array of descriptor features
opposed to a search grid of the protein’s surface (Ferreira et al. 2015; McGaughey et al. 2007).
To accomplish this, descriptor matching algorithms uses receptor-generated property features
similar to those in pharmacophore screening, these descriptors allow ligands to be matched and
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oriented, based on predefined tolerances. Typically, large numbers of orientations are possible,
in which case, each is explored, optimized, and scored to generate the final pose position(s)
(Brooijmans and Kuntz 2003; Millan 2012). The two most commonly cited technologies to
employ this search engine are FlexX and DOCK, both of which operate by means of fragmentgrowing. Despite their differences, these programs all share a generalized scheme for descriptor
matching; usually sets of at least three to four receptor features are matched to the same number
of complementary ligand features, after which an assessment is made to evaluate how well the
ligand atoms match those of the receptor, both geometrically as well as chemically (Dias et al.
2008b; Huang et al. 2010; Warren et al. 2006). However, because of the nature of descriptor
matching, these methods require that subjective decisions be made on the importance of the
various functional groups contained within ligands, because a good choice of the base fragment
is essential for the proper placement and orientation of the ligand (Ferreira et al. 2015). Hence,
poor choices in the weighting of functional groups can significantly affect the quality of the
docking process.
ENERGY-BASED METHODS

Energy-based methods, also known as force field-based

methods, are a class of orientation algorithms that utilize molecular mechanics force fields, in
conjunction with molecular dynamics or energy minimization algorithms, to explore the energy
landscape of each ligand’s surface (McGaughey et al. 2007; Warren et al. 2006). In this method,
an energy minima for a ligand on the surface of a protein must is first identified and then
assessed in terms of complementarity to the receptor (Huang et al. 2010). Notably, such energy
minimizations are a type of local search and thus are only appropriate for optimizing binding
conformations generated by other search engines. Despite the drawback of being a local search
method, force-field based approaches have proven useful when combined with other search
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algorithms that prevent local minima traps. Such modified search algorithms can be seen in
AutoDock, GOLD, and Monte Carlo searches (Bikker et al. 2009; Dias and de Azevedo 2008;
Ferreira et al. 2015).
2.3.2.2 Ligand Sampling Algorithms
SYSTEMATIC

These algorithms aim to explore all the degrees of freedom in a molecule

by imposing slight, incremental variations in the structural parameters to generate all possible
ligand binding conformations (Brooijmans and Kuntz 2003; Huang et al. 2010). The algorithm
operates by probing the energy landscape of the conformational space and, through numerous
iterations of search and evaluation cycles, converges to the minimum energy solution (Ferreira et
al. 2015). For docking, there are three types of systematic searches: exhaustive, fragmentation,
conformational ensemble.
EXHAUSTIVE METHODS

Exhaustive searches are the most straightforward of the

systematic algorithms, in that flexible-ligand docking is carried out by systematically rotating all
rotatable bonds within a ligand at a given interval. The obvious advantage of this method is its
sampling completeness, which can be theoretically perfect given infinitely small increments.
Practically, however, the method is limited by its thoroughness, with higher dimensionality from
increasing rotatable bonds resulting in a conformational explosion. To address this limitation,
some docking programs utilize geometric/chemical constraints to limit conformer generation
during the initial screening stages. FRED and Glide are two popular examples of method.
FRAGMENTATION METHODS

Fragmentation searches utilize incremental construction

algorithms for the placement and subsequent construction of ligands within the active site. In
this process, ligands are initially divided into rigid and flexible regions with one or more rigid
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fragments being designated as an ‘anchor’ (Brooijmans and Kuntz 2003; Kitchen et al. 2004).
Once the rigid anchors have been defined, they are then docked into the active site. After, a
fragment is added in all possible conformations to all placements. The process repeats, with only
the best placements taken to the next iteration, until each fragment has been placed and the
ligand is fully reconstructed (Daga et al. 2014; Rarey et al. 1996).
CONFORMATIONAL ENSEMBLES In conformation ensemble methods, libraries of pregenerated conformations are used to represent ligand flexibility. Library conformations are
typically only calculated once, which serves to reduce computational costs associated with
docking at expense of disk space and granular optimizations. In such cases, exhaustive,
systematic screening is feasible, making stochastic methods superfluous (Danishuddin and Khan
2015; Yuriev et al. 2011). Similarly, ligands devoid of rotatable bonds also lack internal degrees
of freedom, thus requiring the search algorithm to only search the six-translational and rotational
degrees of freedom in the target binding site (Bikker et al. 2009; Ferreira et al. 2015).
STOCHASTIC

In stochastic methods, ligand binding conformations and orientations are

sampled through the introduction of random changes to conformational and
rotational/translational spaces of a ligand. For this, the algorithm generates an ensemble of
ligand conformers that populate a wide range of the energy landscape. This strategy is important
in that it helps avoid the final solution being trapped in a local minima as opposed to the global
energy minima. A pre-defined probability function is then used to evaluate each conformer and
decide whether it should be accepted or rejected. In molecular docking, there are four major
implementations of stochastic algorithms: Monte Carlo methods, evolutionary algorithms, swarm
optimization methods, and Tabu search methods.
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MONTE CARLO METHODS

In Monte Carlo-based methods, an initial configuration is

iteratively refined through a series of random steps that can either accepted or rejected based on a
Boltzmann probability function (Metropolis criterion). In the context of docking, Monte Carlobased methods treat ligands holistically, with new configurations being randomly from
perturbations in rotational, translational, and torsional degrees of freedom. After each move, the
system is minimized and the energy of the new system is calculated. The acceptance or rejection
of the new system is controlled by the Metropolis algorithm (Metropolis et al. 1953), which
ensures that systems with more favorable configurations (lower energy configurations) are
always accepted, while systems higher in energy are only probabilistically accepted.
Consequently, since some higher energy systems are accepted, the search can also proceed
“uphill” on the energy landscape, allowing for some energy barriers to be crossed to find a
deeper energy minima.
GENETIC ALGORITHMS

Genetic algorithms are class of stochastic optimization

techniques that aim address the high computational cost associated with stochastic methods with
methods inspired by the principles of evolution and natural selection. In this method an initial
population of ligand conformers is randomly generated, where the orientation, position, and
conformation of each conformer is encoded in a chromosome of genes for rotation, translation,
and torsion variables. Next, a set of genetic operators (mutation, crossover) is then applied to
this population to produce a new generation, whereby individuals with superior fitness have a
higher likelihood of ‘carrying over’ into the next generation. This process continues until a
particular termination criterion is reached, such as a minimal root-mean-square deviation
(RMSD) of the fittest individual, a constant optimal fitness, or simply a maximum number of
generations.
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SWARM OPTIMIZATION METHODS

Swarm optimization methods attempt to

discover an optimal solution in a search space by modeling swarm intelligence. In the method,
movements of a ligand mode, represented by particles, through the search space is influenced by
its own search history and by the information of the best positions of its neighbors (Huang et al.
2010; Janson et al. 2008).
TABU SEARCHES

In Tabu search methods, the probability of acceptance of a configuration is

dependent on the previously explored areas in a ligand’s conformational space. The random
change will be accepted if the RMSD between the current ligand binding conformation and any
of the previously recorded solutions is more than the cutoff; otherwise, the random change will
be rejected (Huang et al. 2010; Westhead et al. 1997).
2.3.2.3 Scoring Functions
Current docking technologies typically utilize scoring functions in one of two ways. One
uses the full scoring function to evaluate a protein-ligand conformation, after which, a
subsequent round of modifications to the system is carried out by the search algorithm, and then
the same scoring function is re-applied to evaluate the new structure The alternative, instead,
applies a two-tier scoring function, in which, a reduced function is used to direct the search and
is followed by a more rigorous scoring function to rank the final structures. To estimate the
binding potential for a ligand to a protein’s active site, current docking technologies typically
employ any of three differing classes of scoring functions: force-field methods, empirical
methods, and knowledge-based methods (Charifson et al. 1999; Clark 2002; Moitessier et al.
2008; Muegge et al. 2001; Muegge and Rarey 2001; Sprous et al. 2002).
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Force Field

Force field-based scoring functions are a class of scoring functions that

estimate the binding affinity of a protein-ligand complex by summing the contributions of
bonded (bond stretching, dihedral variation, and angle bending) and nonbonded terms (van der
Waals and electrostatics) in a general master function (Ferreira et al. 2015). The Coulomb and
Lennard-Jones potentials, representing the electrostatic and van der Waals terms respectively,
commonly used as nonbonded interaction terms in force fields are well suited to sensitively
monitor the geometric quality of a binding mode. Such force field functions are derivative of
both experimental and ab initio quantum mechanics; as they depend on empirical
parameterization, care must be taken to ensure that the force field is adequately parameterized
for the molecules being investigated (Danishuddin and Khan 2015; Sotriffer 2015).
Many docking programs make use of force field terms to score and optimize binding
poses, with Glide (Friesner et al. 2004) and AutoDock (Goodsell et al. 1996; Morris et al. 1996)
being two prominent examples. However, pure force field-based scoring functions suffer from a
major limitation, in that they ignore most solvent effects and solute entropies, and the calculated
scores are just energies or enthalpies, opposed to free energies. Hence, force field terms alone
are not sufficient for ranking different ligands or estimating binding affinities. Accordingly, for
such a task, desolvation terms, at a minimum, are needed for accurate predictions. Shoichet et al
was the first to add the effects of the solvent on protein-ligand interactions using an implicit
solvent model (Bikker et al. 2009). Generalized Born/Surface Area (GB/SA) (Ghosh et al. 1998)
and Poisson-Boltzmann/Surface Area (PB/SA) (Baker 2005) are archetypal examples of implicit
solvent models incorporated into docking programs (Mysinger and Shoichet 2010; Wei et al.
2002). In addition to solvent related limitations, pure force field based scoring functions also
suffered from charge bias, causing a phenomenon in which charged molecules tended to outscore
37

other less charged molecules (Danishuddin and Khan 2015). Newer strategies in force field
based scoring functions now typically employ a tiered approach to score and post-process the
generated pose predictions while also taking into account implicit solvent contributions such as
those described in the Generalized Born and Poisson-Boltzmann methods (Huang et al. 2010;
Mysinger and Shoichet 2010). These enhanced scoring functions typically result in better
agreement with true binding free energies and the predicted rankings of ligands.
Empirical

Regression analysis among structural descriptors and binding data of

protein-ligand complexes provides another approach to scoring functions. Because of their
reliance on experimental data for both crystal structures and binding energies, the resulting
functions are typically termed “empirical scoring functions” (Sotriffer 2015; Wang and
Busemeyer 2013). Empirical scoring functions are based on the assessment of localized,
chemically intuitive interactions between a ligand and protein in a noncovalent complex.
Following the assumption of additivity, the scoring function is fit to reproduce experimental
data, such as binding affinities, by summing a set of weighted empirical energy terms such as,
electrostatic energy, hydrogen bonding energy, van der Walls energy, entropy energy,
desolvation energy, and hydrophobicity energy (Kitchen et al. 2004; Sotriffer 2015). The
conceptual design of empirical scoring functions derive from the idea that binding energies can
be approximated by a sum of individual, uncorrelated terms. When dealing with many
complexes of known structure and affinity (training set), the descriptors are first calculated and
then correlated with the experimental binding affinity by assigning weights to regression analysis
process or other related statistical methods, such as machine learning techniques (e.g., Support
Vector Machines) (Ballester and Mitchell 2010; Sotriffer 2015; Zilian and Sotriffer 2013). The
resulting function is then fit to score protein-ligand complexes and obtain binding energy
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estimates. The quality of empirical scoring functions critically depends on the size, composition,
and quality of the training set, with respect to both structure and affinity data (H. J. Bohm et al.
1999; Kalliokoski et al. 2013; Tame 1999).
Knowledge based

Structural databases of protein-ligand complexes contain a wealth of

information beyond the value of the individual structure. Knowledge-based scoring functions
make use of this structural information. In essence, knowledge-based functions are aim to
reproduce experimental binding conformations in contrast to empirical functions which are
trained to reproduce binding energies. Generally, this type of scoring function is modeled using
relatively simple interaction-pair potentials which are based on their frequency of occurrence in
the training set being used (Kitchen et al. 2004; Sotriffer 2015). The method operates on the
assumption that close intermolecular interactions between certain types of atoms or functional
groups occur more frequently than one would expect by a random distribution are more likely to
be energetically favorable and therefore contribute positively to binding affinity(Wang and
Busemeyer 2013). Compared to empirical and force field scoring functions, the knowledgebased scoring functions offer a good balance between speed and accuracy. As with empirical
scoring functions, a disadvantage of knowledge based scoring functions is that fundamentally
rely on information implicitly encoded in limited sets of protein-ligand complex structures,
making their predictiveness limited by the training set size and quality. (Ferreira et al. 2015;
Huang et al. 2010).
2.4 Ligand-Based Approaches
Ligand-based approaches capitalize on the fact that ligands similar to bioactive ligands
are, themselves, more likely to be bioactive than random ligands. Generally, such approaches
commonly consider 2D or 3D chemistry, shape, electrostatics, and interaction points to assess
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similarity, and are most frequently employed when a particular biological target is unknown or
when the crystal structure of a known target is unavailable (Acharya et al. 2011; Bacilieri and
Moro 2006; Maggiora and Shanmugasundaram 2011). The major focus lies of these methods
lies on three related issues: (i) measure ligand similarity fast and accurately, (ii) devise
techniques for molecular representation, alignment, and feature matching, (iii) assess
relationships between structure and activity (SAR) using information contained within the
ligands (Braga et al. 2014; Maggiora and Shanmugasundaram 2011).
2.4.1 Similarity Based Methods
For any two molecules, the number of features that can be directly compared are quite
large (i.e. shape, size, charge, conformation, etc.). In addition, numerous descriptors and
algorithms can be used to capture and quantify essential characteristics that can be used for
similarity metrics (Amaratunga et al. 2015; Braga et al. 2014; Wawer et al. 2008). For these
reasons, many types of similarity measures exist.
2D Fingerprints and Structural Keys

Fingerprint screening, is a fast, relatively simple

screening method that using binary strings ─ encoding the presence or absence of substructural
fragments ─ to measurement intermolecular structural similarity between a target and reference
molecule (Cabrera et al. 2015). Using a fragment dictionary, a set of chemical features for each
molecule is defined and a bit set to either zero (0) or one (1), depending on whether the
substructure exists in the molecule or not. This gives rise to a chemical fingerprint holding
molecular descriptors for the target and reference molecules in the form of a binary bit string
(Willett 2006). A comparison of the bitstrings of each molecule (target and reference), allows
for a calculation of the similarity among the two molecules using the Tanimoto coefficient.
Despite 2D fingerprints having proved valuable to drug discovery projects, they suffer from
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several weaknesses. For example, changing a single atom in a ring structure may change the
fingerprint from being nearly identical to almost completely different. Furthermore, 2D
fingerprints lack spacial information. Two compounds that have very different structural
connectivity can nonetheless adopt similar 3D orientations and thus confer similar biological
effects (Braga et al. 2014).
3D Shape Methods

3D shape-based approaches, or Gaussian-based methods, represent each

atomic site within a molecule with a spherically symmetric Gaussian function and measures the
volume over all Gaussians. Using the amount of volume overlap, estimations of shape similarity
can be assessed and scored (Cabrera et al. 2015; Haigh et al. 2005). However, calculations of
volume overlap between two molecules are highly dependent on their relative position in 3D
space, thus, for 3D-shape based methods to accurately assess similarity, they must first obtain the
best possible superimposition through an optimization or fitting procedure (Ballester et al. 2009;
Grant et al. 1996). For scoring, only volume overlap of the optimally aligned molecules is
calculated, making the comparison practically independent of the atom types and bonding
patterns present in both query and search molecules. As with the fingerprint methods, the
Tanimoto coefficient is the most common metric used to asses volume overlap (Peltason 2008;
Peltason et al. 2010; Peltason and Bajorath 2011).
2.4.2 Pharmacophore Based Methods
The concept of the pharmacophore, in the modern sense, was first put forth in the late
1960s by Monty Kier. His idea, simply stated, was to create a 3-D spatial arrangement of
functional groups essential for biological activity; a three–dimensional pattern that emerges from
a set of biologically active molecules (Kier and Roche 1967). For drug design, the features of a
pharmacophore represent the location and type of functional group that a candidate molecule
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should possess for it to be bioactive against a particular target (Leach et al. 2010). Traditionally,
pharmacophore models were comprised of the six main chemical features: positive charged
group, negative charged group, hydrogen bond acceptor, hydrogen bond donor, hydrophobic
group, and aromatic ring. In modern practice, a pharmacophore model can be established in
either a ligand-based manner, by superimposing bioactive molecules and extracting the location
and type of shared chemical features essential for bioactivity, or in a structure-based manner, by
probing likely interaction points between the ligand(s) and macromolecular target. Both
approaches have been applied successfully and extensively in virtual screening (Akram 2015;
Braga et al. 2014; Guner and Bowen 2014; Villoutreix et al. 2009).
In the absence of a macromolecular target structure, ligand-based pharmacophore
modeling has become an indispensable tool for the early stages of drug discovery. Typically this
involves extracting common chemical features from the 3D structures of several known bioactive
ligands, collectively generating a map of the essential interactions between the ligand and the
macromolecular target In general, pharmacophore generation using multiple ligands involves
two main steps: the creation of conformers based on the conformational flexibility and the
subsequent alignment of select conformers, and the determination of shared chemical features
that represent essential interaction points with the receptor. The handling of ligand
conformational flexibility and conducting conformer alignments represent the key techniques in
ligand-based pharmacophore modeling, but also the major difficulties associated with the
technique (Akram 2015; Guner and Bowen 2014; Stahura and Bajorath 2005; Xue et al. 2005).
Structure-based pharmacophore modeling, on the other hand, directly incorporates the 3D
structure of a macromolecular target. The protocol involves an analysis of the chemical features
of the active site and their spatial relationships, from which a subsequent pharmacophore model
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can be assembled with complementary features (Pirhadi et al. 2013). The structure-based
pharmacophore modeling approach can be further classified into two subcategories: receptorligand-complex-based and receptor-(without ligand)-based. The receptor-ligand-complex-based
approach is convenient in pinpointing the ligand-binding site on the receptor and visually
determining the key interaction points between ligands and macromolecule. The obvious
limitation of this approach is the need for crystal structure of the receptor–ligand complex. This
can be overcome by the receptor-only approach (Akram 2015). However, without a bound
ligand, identifying key interaction points within the active site is extremely difficult, often
leading to a pharmacophore model containing unnecessary features. Hence, when possible, a
receptor-ligand based approach should be implemented (G. Bohm and Jaenicke 1992; Horvath
and Jeandenans 2003; Horvath 2011).
2.4.3 QSAR Based Methods
The last and most frequently utilized ligand-based method is the quantitative structure-activity
relationship, QSAR. QSAR models are a means used to correlate molecular activities with
physiochemical descriptors from a set of related compounds. QSAR modeling techniques can be
very useful in predicting bioactivity in experimentally untested compounds (Braga et al. 2014).
Furthermore, QSARS have proven helpful in lead identification during the early stages of virtual
screening as well as a means to prioritize synthetic efforts (Jorissen and Gilson 2005). Despite
their usefulness, QSARS require a significant amount of accurate kinetics data to be employed.
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CHAPTER 3: INVESTIGATING COMBINATORIAL APPROACHES IN VIRTUAL
SCREENING ON PFKFB3: A CASE STUDY FOR SMALL MOLECULE KINASES
3.1 Abstract
Fruitful efforts toward improving the predictiveness in tier-based approaches to virtual
screening (VS) have mainly focused on protein kinases. Despite their significance as drug
targets, small molecule kinases have been rarely tested with these approaches. In this section, we
investigate the efficacy of a pharmacophore screening-combined structure-based docking
approach on the human inducible 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase, an
emerging target for cancer chemotherapy.
Six out of a total 1,364 compounds from NCI’s Diversity Set II were selected as true actives
via throughput screening. Using a database constructed from these compounds, five programs
were tested for structure-based docking (SBD) performance, of which, MOE showed the highest
enrichments and second highest screening rates. Separately, using the same database,
pharmacophore screening was performed, reducing 1,364 compounds to 287 with no loss in true
actives, yielding an enrichment of 4.75. When SBD was retested with the pharmacophore filtered
database, 4 of the 5 SBD programs showed significant improvements to enrichment rates at only
2.5% of the database, with a 7-fold decrease in an average VS time. Our results altogether
suggest that combinatorial approaches of VS technologies are easily applicable to small molecule
kinases and, moreover, that such methods can decrease the variability associated with singlemethod SBD approaches.
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3.2 Introduction
Compared to the traditional, costly methods of high throughput screening (HTS), the
search for the potential drugs with computational technologies, also called virtual screening
(VS), continues to grow in popularity (Sousa et al. 2010; Tuccinardi 2009; Villoutreix et al.
2009). Unlike HTS, which requires constant human intervention, even with the usage of
robots, VS needs only a good computational resource and, more attractively, can be
performed in a ‘fire-and-forget’ manner with only minimal human input once properly
started. Although each has its own distinct advantages, these methods share a common goal
in that they both aim to identify a small number of true biological positives amidst a vast
amount of biological negatives (Klebe 2006; Parker and Bajorath 2006).
A computational drug search, or VS, is carried out to find biologically positive
compounds from compound databases, which typically contain molecular information on
compounds that range in number from thousands to millions. Depending on the screening
factors, VS involves diverse strategies: molecular features of the known ligand
characteristics, pharmacophore screening (PhS); ligand alignments based on both structural
and physical characteristics of ligands, ligand similarity analysis (LSA); and the
interactional relationship between ligands and their target receptors, structure-based docking
(SBD) (Guido et al. 2008). Depending on the availability and capacity of computational
resources, an overall strategy of VS can be varied to employ either one, or combinations, of
these technologies to appropriately meet the user’s needs.
Assuming that data handling is performed in an organized manner, PhS can be carried
out in a very short amount of time using even a personal desk computer. SBD, on the other
hand, requires an extensive amount of calculations of Gibbs free energy changes involved in
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the various ligand receptor interactions (Guido et al. 2008). Consequently, a high capacity
computational resource, such as a processor cluster, is usually necessary for moderate-tolarge SBD projects. However, even with such a facility, the amount of required computation
time is often still very considerable, a circumstance owing to the fact that the vast majority
of SBD time is consumed performing extensive calculations on outright negatives simply
because of low hit rates associated with non-enriched databases. To improve the cost
efficiency of SBD, efforts have been made to combine SBD with other less-time consuming
technologies (Maiorov and Sheridan 2005). As a result, tiered screening strategies, in which
ATP was considered as single ligand, have been successful in protein kinases (PK), one of
the most popular drug targets up to date (Guido et al. 2008; K. Lee et al. 2010; Nagarajan et
al. 2010; Workman and van Montfort 2010).
Despite their significance as drug targets, studies for strategic VS of small molecule
kinases (SMK) are extremely rare compared to those of PK (Marsden and Knapp 2008;
Workman and van Montfort 2010). To explore how well the concepts of tiered screening
translate to SMK, we sought to design a dual-step screening protocol that could accurately
and efficiently identify potent inhibitors through a combination of pharmacophore screening
(PhS) and structure-based docking (SBD). Both PK and SMK have a second substrate
pocket in addition to the widely conserved ATP pocket. Compared to PK, SMKs can have
one, or possibly two, ligands that can bind the non-ATP binding site, most of which are
known from biochemical/structural characterizations. We speculated that those known
ligands may serve as a good resource of pharmacophore and may serve to add more target
specificity. Thus, our study was targeted at the second substrate binding site, the pocket for
the acceptor of the phosphoryl group from ATP.
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For this project, the human inducible 6-phosphofructo-2-kinase/fructose-2,6bisphosphatase (PFKFB3), a newly emerging drug target for potential cancer
chemotherapeutics, was taken as the receptor (Chesney 2006). The kinase domains of the
four PFKFB isoforms catalyze the synthesis of fructose-2,6-bisphosphate (F-2,6-P2), which
is the most potent allosteric stimulator of glycolysis, using adenosine triphosphate (ATP) as
the phosphoryl donor and fructose-6-phosphate (F-6-P) as the acceptor (Pilkis et al. 1995;
Rider et al. 2004). Predominantly expressed in neoplastic cells by the action of HIF-1
among the four isoforms, PFKFB3, with its kinase activity at least 10x that of the second
most active isoform, rapidly increases the level of Fructose-2,6-bisphosphate (F-2,6-P2)
(Kim et al. 2006; Yalcin et al. 2009). As a result, glycolysis in neoplastic cells such as
cancer is very active, which has been long known as the Warburg effect (Hsu and Sabatini
2008; Kroemer and Pouyssegur 2008). Recent studies have suggested that PFKFB3, whose
expression is induced during cancer growth, is one of the most causative molecules of the
Warburg effect (Atsumi et al. 2002; Yalcin et al. 2009). To explore the possibility of
PFKFB3 as a new cancer therapeutic target, we determined the crystal structure of PFKFB3
to 2.1Å and elucidated the catalytic mechanism for F-2,6-P2 synthesis at the molecular level
(Kim et al. 2006). The resulting molecular structure/function information has been used as
the foundation of this study.
In this report, we investigate the efficacy of combinatorial screening of PFKFB3
targeting for the F-6-P site. To evaluate the efficacy of our tiered approach, we developed
our own database of active/non-active molecules from the National Cancer Institute’s (NCI)
Diversity Set II through a biochemical throughput study, since no non-ATP datasets of
competitive inhibitors for the second substrate. Using the actives as reference compounds,

47

we explored applications from the two most common approaches in computational drug
discovery: pharmacophore screening and structure based docking. Herein, we present the
results from our combinatorial approach, demonstrating the enrichment of a 1,364
compound database, containing six true actives ‘T-actives’, to a resultant database of 287
compounds, still containing six ‘T-actives’, while using only one seventh of the
computational resources required for standard docking procedures.
3.3 Materials and Methods
Biochemical throughput screening.
The recombinant human PFKFB3 was expressed and purified as described elsewhere.
The 1,364 individual compounds of NCI’s Diversity Set II were acquired from the NCI.
The 2-kinase activity assay for throughput screening was performed using a F-2,6-P2 assay
modified for 96-well plates from the conventional method (van Schaftingen et al. 1982).
This assay consisted of two sequential steps: F-2,6-P2 production by PFKFB3 and allosteric
activation of PFK-1 by produced F-2,6-P2. The first reaction, F-2,6-P2 synthesis by
PFKFB3, was started by adding 130 nM PFKFB3 to mixtures containing 20 mM pH 8.0
TES, 1 mM DTT, 2 mM MgCl2, 50 µM F-6-P, 50 µM ATP, 0.5% Tween, and 10 µM of
each inhibitor. This reaction was allowed to run for 10 minutes at 25°C and then stopped by
the addition of 0.1 M KOH. Aliquots of 1-4 µL of the first reaction were transferred, after
pH neutralization, to the reactions of the second step, which consisted of 50 mM pH 8.0
Tris-HCl, 0.2 mM NADH, 5 mM DTT, 1 mM F-6-P, 2 mM MgCl2, 0.70 units/mL Aldolase,
0.45 units/mL GDH, 0.60 units/mL TIM, and 10 mU PPi:PFK. The reactions of seconds step
were started by adding 0.5 mM sodium pyrophosphate (PPi) and were then measured for
changes in absorbance at 340 nm over a period of 30 minutes.
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For molecules showing strong inhibition in the throughput assay, a study of the steadystate inhibition kinetics was carried out using a method in which the concentrations of F-6P, ATP, and/or inhibitors were varied according to experimental purposes.
Ligand Library Design.
The virtual ligands of NCI’s Diversity Set II were obtained from NCI’s Developmental
therapeutics program (DTP). The ligands were acquired in SMILEs format and standardized
using a template to ensure that each was minimized, pH adjusted, and devoid of salts and other
non-ligand contaminants. Additional adjustments, such as explicit hydrogens and force fields
were added in a program-dependent fashion depending on manufacturer recommendations.
Using the standardized ligand database, an additional conformer database was generated for
pharmacophore filtering. For this, MOE was used to generate a conformer database based on
default settings with a maximum of 250 conformers per ligand and no post-generation
refinement.
Structure-Based Virtual Docking.
Virtual docking was carried out using 5 different programs, DOCK, VINA, FlexX, MOE,
and GOLD in an effort to determine the suitability of each for PFKFB3 screening (Ewing et al.
2001; Group 2010; G. Jones et al. 1997; Rarey et al. 1996; Trott and Olson 2010). For this, the
protein structure ‘2AXN’ was used as the receptor macromolecule for docking (Kim et al. 2006).
The details of program-specific conditions are included in Supplemental Information.
Pharmacophore Screening.
MOE was used to generate pharmacophores from three molecules known to bind to the
F-6-P pocket of the PFKFB3: Fructose-6-Phosphate (F-6-P), Ethylenediaminetetraacetic acid
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(EDTA), and Phosphoenol Pyruvate (PEP). The conformations for these molecules were
obtained from the structural data (PDB ID: 2AXN, 2DWO, 2I1V, 2DWP). By superimposing the
conformers, property features were extracted and merged and tolerance values were adjusted in
accordance with results through retro-fitting. After refinement, eight features were chosen to be
included in the final pharmacophore map; however, only 5 features are required to be met at any
one time for a compound to pass the filter. Additionally, inclusion and exclusion spheres were
added and constraint allowances were adjusted for preference. All pharmacophore searches were
carried out within MOE.
3.4 Results
Biochemical Throughput Screening.
To generate a framework of actives and non-actives for VS, a throughput study of 1,364 NCI
compounds was carried out. The inhibition extent of 10 M of each compound, in substrate
saturation conditions, was quantified and the results of the top 50 compounds are shown in Fig.
3.1. An arbitrary cutoff was chosen at 75% inhibition to describe compounds that were to be
considered ‘potential’ actives. Based on this cutoff, 10 compounds were identified from the
original 1,364.
To select the true positives, the 10 potential actives were subsequently tested for specificity for
the F-6-P site, because the VS was targeted for the F-6-P site. Using conventional steady state
inhibition kinetics, 6 compounds were selected as the ‘true actives (T-actives)’ and listed in Fig.
3.2. All T-actives exhibit competitive inhibition against F-6-P and uncompetitive against ATP, as
a representative example, NSC278631, is shown in Fig. 3.3. The Ki’s for each compound was
determined to be at or below 20 µM.
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Figure 3.1. Identification of potent PFKFB3 inhibitors via a single-dose (10 μM) primary
screening assay. The top 50 PFKFB3 inhibitors of NCI’s Diversity set II are shown in relation to
four experimental controls. Inh1 and inh2 are in-house inhibitors that have been tested and shown
to target the PFKFB3 kinase domain. The controls, Pos and Neg, depict the uninhibited presence
and complete absence of PFKFB3, respectively, and thus were used to represent the theoretical
maximum and minimum inhibition values by which all screening compounds were compared.

Figure 3.2. Inhibition for the PFKFB3 2-kinase by NSC278631. A double-reciprocal plot shows
the competitive inhibition for NSC278631 against F6P. The lines represent varying inhibitor
concentrations and were generated by data fitting using the program GraphPad Prism.
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Figure 3.3. The selected actives from the throughput screening of the NCI Diversity Set II.

Pharmacophore Screening.
Using ligands already known to bind to the F-6-P site from crystallographic evidence, namely, F6-P, F-2,6-P2, EDTA, and PEP, a pharmacophore model was built and used to screen the NCI
diversity set via MOE’s pharmacophore screening module (Fig. 3.4) (Kim et al. 2006; Kim et al.
2007). Overall, from this filtering process, the database size was reduced from 1364 to 287
ligands while retaining 6 out of 6 ‘T-actives’. The results of this procedure demonstrate a
significant reduction in non-actives and no reduction in actives. The total screening time was 206
seconds on a 2GHz processor with a conformer database creation time of 9911 seconds.
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Figure 3.4. Pharmacophore map used in PFKFB3 virtual screening. (a) A ribbon diagram of
PFKFB3 in complex with three ligands, ADP, EDTA, and F-6-P (PDB ID: 2AXN). The boxed
ligand, EDTA, is occupying the F-6-P site of the kinase, which is the target site for our screening
protocol. (b) A magnified view of the F-6-P site including a pharmacophore feature map. The
feature map consists of 8 spheres of varying sizes and chemical properties, with at least 5 being
needed to be met for a ligand to pass the filter. Pharmacophore features: Red (AccP|AccS), LightBlue (HydS|AccP), Magenta (ML&(AccS|AccP)), Green (HydP|HydS), Dark Red
(Ani&(AccS|AccP)), Gray (ML).

Performance comparisons of docking programs.
Because it has been demonstrated in numerous studies that the efficacy of a SBD
program directly ties to the target protein, we chose to test the individual performances of several
SBD programs. Using PFKFB3, a full database evaluation was conducted to compare the
enrichment factors of five popular SBD technologies (Fig. 3.5). The results revealed that each of
the tested SBD technologies significantly enriched the NCI diversity set II database. However,
as seen in other studies, the enrichment rates varied significantly according to the SBD
technology (Kruger and Evers 2010; Li et al. 2010; Plewczynski et al. 2011). For comparison
purposes, we investigated the enrichment at two database sizes, 2.5% and 10%. MOE performed
best, showing higher enrichments at all database sizes. The other SBD programs were more
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varied in their performances with VINA having the second highest enrichment rates at 2.5% and
GOLD at 10%.
Combinatorial Screening Efficacies.
To measure the efficacy of the combinatorial screening protocol, the pharmacophore
filtering results were subsequently docked using each of the SBD technologies. For this, the PhS
enriched database, consisting of the 287 hit molecules with all actives present, was docked and
the enrichment rates were evaluated at 2.5% and 10% database sizes (Fig. 3.6). The results
demonstrate improved enrichment rates for four of the five SBG technologies at 2.5% database
size and five of five at 10% database size compared with docking-only methods. Additionally, it
was determined that the application of the combined protocol, greatly reduced the variability of
the incorporated SBD technologies, changing the enrichment differences between the highest and
lowest scoring technologies from 13 to 6.5 and 4.9 to 3.2 at 2.5% and 10% database sizes,
respectively. Reductions in the overall time were also witnessed, showing nearly a 7-fold
decrease in the average total time for a complete database screening using the tiered approach.
3.5 Discussion
In this work, the enrichment capability of a commonly employed, tier-based virtual
screening approach was evaluated using the small molecule kinase 6-Phosphofructo-2kinase/Fructose-2,6-bisphosphatase (PFKFB3). For this, biochemical throughput data was
generated using the National Cancer Institute’s Diversity Set II compound library, serving as a
metric upon which enrichment rates were calculated (Fig. 3.1). The aim was to evaluate the
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Figure 3.5. Enrichment Comparison of Popular SBD Technologies on PFKFB3. Full Database
enrichment rates were calculated for comparison between VINA (red), MOE (blue), FlexX (green),
DOCK (purple), GOLD (gray), and random (dotted).
efficacy of the combined pharmacophore-docking protocol in relation to docking-only methods
using a representative protein from the small molecule kinase family. Additionally, an
investigation into the predictiveness of the major docking technologies was conducted; seeking
to identify which offered best enrichments for PFKFB3.

55

Figure 3.6. Performance comparison between sequential and non-sequential virtual screening
protocols. (a and b). Calculated enrichment rates at differing database sizes for Docking (D) and
Pharmacophore+Docking (P+D) screening protocols. Shown on the x-axis are the five docking
programs, each of which was evaluated individually, and, in conjunction with, a pharmacophore
filter as previously described.
(c) Measured screening times for Docking (D) and
Pharmacophore+Docking (P+D) screening protocols. Shown on the x-axis are the five docking
programs, each of which was evaluated individually, and, in conjunction with, a pharmacophore
filter as previously described.
The results of our investigation revealed that tiered screening, in the case of PFKFB3, in
which, pharmacophore filtering precedes structure based docking, is clearly favorable to any
individual screening method, both in efficacy and efficiency (Fig. 3.6). An analysis of our results
can be evaluated in terms of three factors: speed, accuracy, and consistency.
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The accuracy of in silico predictions is always a critical factor of virtual screening. Hence,
our investigation into tiered approaches of virtual screening initially focused on differences in
enrichment rates between single SBD and combined PhS-SBD approaches. The results from our
testing revealed that, in the case of PFKFB3, the enrichment factors of the combinatorial strategy
was always comparable to, or in excess of, the values demonstrated from the single-run structure
based simulations. Such results were not entirely unexpected when considering the results of
previous studies demonstrating similar findings for single-ligand proteins and protein kinases
(Swann et al. 2011; Tan et al. 2008). However, since no similar, large-scale, studies of small
molecule kinases are yet published, it was not known if such trends would extend to small
molecule kinases. The findings presented here should serve to lessen our knowledge gap
involving the enrichment efficacy of tiered approaches to virtual screening for small molecule
kinases.
Another finding reported here involves the changes to SBD consistency when incorporated
into tiered-based approaches. From our single-method docking results, it was seen that vast
differences exist between the enrichment rates of differing technologies. However, upon analysis
of the PhS-SBD tiered approach, it was clear that most of the differences in enrichment among
the SBD technologies efficacy had significantly lessened. Such findings are promising, in that
they help to lessen the need to test multiple SBD technologies for any given project. Because it
is well known that different SBD technologies offer differing performances depending on the
target macromolecule, such findings suggest that the need to test many SBD technologies can be
significantly lessened by using tiered approaches.
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Lastly, and most apparent among our findings, was the obvious advantage of the tieredbased approach in reducing the computational time necessary to screen the Diversity Set II
database. Despite having higher enrichment rates, the tiered screening was, on average, 7-fold
faster than its single-run counterparts. The principle behind such an increase hinges on the role of
pre-filtering. By using a loose, lightly-selective filter early on, many of the more egregious
ligands can be removed prior to the computationally intensive step of docking, thus significantly
reducing the time necessary for any virtual screening project.
The results altogether indicates that a combinatorial approach for VS is far more efficient
than a blind run of time- and resource-consuming simulated docking. However, it has to be
admitted that there are some shortfalls in combinatorial approaches. First, it requires at least one
ligand that is already known to bind to a target receptor and, practically, the more the better. In
reality, this problem is almost ignorable for most of the active drug target proteins. It is because
only a few proteins whose functions are not known are selected as drug targets. For most cases,
when a protein was selected as a drug target, its function is clearly defined and, accordingly, at
least one or two ligands are already known.
Second, as apparent from the results of our studies, there is no missing ‘T-actives’ from the
pharmacophore screening. And while this is not necessarily a problem, and was desired as part of
our ultimate aim, such a favorable ‘T-active’ recovery from pharmacophore screening is
dependent upon the experience of the modeler. For this project, the creator set out with the
intention of designing a loosely selective map rather than one maximizing enrichment at the
expensive of recovered ‘T-actives’. Such a choice was made upon the basis of the size of the
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database to be screened, however, we do not anticipate that alternative selections based on
enrichment preferences, would dramatically influence the benefits of combinatorial screening.
In this paper, we demonstrate that the combined use of ligand- and structure-based screening
for small molecule kinases can decrease screening times and increase enrichment rates as
compared with single step screening approaches.
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CHAPTER 4: CRYSTAL STRUCTURE OF 6-PHOSPHOFRUCTO-2KINASE/FRUCTOSE-2,6-BISPHOSPHATASE (PFFKB2) AND THE INHIBITORY
INFLUENCE OF CITRATE ON SUBSTRATE BINDING.
4.1 Abstract
The heart-specific isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
(PFKFB2) is an important regulator of glycolytic flux in cardiac cells. Here, we present the
crystal structures of two PFKFB2 orthologues, human and bovine, at resolutions of 2.0 and 1.8Å,
respectively. Citrate, a TCA cycle intermediate and well-known inhibitor of PFKFB2, was
present in the 2-kinase domain of both orthologues, occupying the fructose-6-phosphate bindingsite while also extending into the γ-phosphate binding pocket of ATP. This steric and
electrostatic occlusion of the γ-phosphate site proved highly consequential to the binding of cocomplexed ATP analogues. The bovine structure, which co-crystallized with ADP, closely
resembled the overall structure of PFKFB isoforms, with ADP mimicking the catalytic binding
mode of ATP. The human structure, on the other hand, co-complexed with AMPPNP, which,
unlike ADP, contains a γ-phosphate. The presence of this γ-phosphate made adoption of the
catalytic ATP binding mode impossible for AMPPNP, forcing it to bind atypically with
concomitant conformational changes to the ATP binding-pocket. Inhibition kinetics were used
to validate the structural observations, confirming citrate’s inhibition mechanism as competitive
for F6P and mixed for ATP. Together, these structural and kinetic data establish a molecular
basis for citrate’s negative feed-back loop of the glycolytic pathway via PFKFB2.
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4.2 Introduction
The bifunctional enzyme, 6-phosphofructo-2kinase/fructose-2,6-bisphosphatase
(PFKFB), catalyzes both the synthesis and hydrolysis of fructose2,6-bisphosphate (Fru-2,6-P2) as
a functional homodimer (C. Wu et al. 2006). The dual enzymatic activities are provided by the
two separate catalytic domains existing in a single protein subunit, to control the concentration of
Fru-2,6-P2, the most potent allosteric activator of 6-phosphofructo-1-kinase (PFK), the ratelimiting enzyme of glycolysis (El-Maghrabi and Pilkis 1984; Pilkis and Granner 1992; Pilkis et
al. 1995). An elevated cellular concentration of Fru-2,6-P2 increases glycolytic flux, whereas a
lowered concentration of Fru-2,6-P2 decreases glycolysis. Reflecting the diversity of tissues and
their physiological functions, different tissue-specific isoforms of PFKFB from four distinct
genes (pfkfb1-4) are expressed, each with different kinetic properties, and a single isoform
generally predominates in each tissue: PFKFB1, the liver form; PFKFB2, the heart form;
PFKFB3, the inducible form; and PFKFB4, the testis form (Okar et al. 2001).
Because of the uniqueness in its structure/function relationships, the PFKFB enzyme
system has long been targets of structure/function studies. As a result, a significant amount of
functional data has been produced and the crystal structures of the rat liver Fru-2,6-P2ase
domain, the rat testis form (PFKFB4), the human liver form (PFKFB1), and human cancer form
(PFKFB3) have been determined (Hasemann et al. 1996; Kim et al. 2006; Y. H. Lee et al. 2003).
These data altogether allowed us to understand the molecular mechanism of catalytic reactions
and regulation of this enzyme system. Some are now serving as a molecular foundation for
development of therapeutics for diabetes and cancer (Garber 2004; A. Minchenko et al. 2002).
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However, one of the most fundamental questions yet to be answered about this enzyme
system is how each PFKFB isoform performs its differential function in hosting tissues that have
specific physiological roles and, accordingly, different optimum conditions for glucose
metabolism. Reflecting such differences, the PFKFB isozymes have been shown to have
different kinetic properties, as summarized in Figure 4.5. These kinetic differences suggest that
glucose metabolism is uniquely related to the physiological roles of the given tissues and not just
a simple housekeeping function for energy production (Y. H. Lee et al. 2003; Pilkis et al. 1995).
As an effort to address the tissue-type specifically differentiated structure/function
relationships of PFKFB isoforms, we determined the crystal structures of heart isoforms of
PFFKB, PFKFB2, from both H. sapiens and B. taurus. Analysis of their structures and kinetics
in comparison with those already known from the previous PFKFB studies suggested a
regulatory mechanism as yet unknown and we introduce the results here.
4.3 Materials and Methods
Crystallization of PFKFB2 Homologs
The human and bovine PFKFB2 isoforms with 6xHis tagged at the N-termini were
overexpressed in Escherichia coli BL21 C41(DE3) and purified using Ni-NTA affinity columns
in conjunction with SP Sepharose cation exchange columns. Following purification by SP
Sepharose, the proteins were dialyzed with pH 8.0 20 mM TrisHCl, 10 mM NaPi, 5 mM βMercaptoethanol , and 5% glycerol and then concentrated to 8.0 mg/ml with Millipore
centrifugal filter concentrators. Crystallization of the bovine PFKFB2 (bPFKFB2) were prepared
via sitting drop vapor diffusion using a 1:1 mixture of protein sample to a mother liquor, pH 7.5
100mM HEPES, pH 7.0 0.5% tacsimate, 13-16% polyethylene glycol 3350, and 3% dioxane.
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The crystals were grown to a dimension of 0.2 x 0.2 x 0.05 mm within 2-3 weeks of incubation
at 20°C. Crystals of the human PFKFB2 (hPFKFB2) were also prepared with the sitting drop
vapor diffusion method using a mother liquor, pH 6.0 100mM MES, 0.5-3.0% polyethylene
glycol 8000, 13-16% polyethylene glycol 3350, and 3% dioxane. Data quality crystals of
hPFKFB2 were grown after 3-5 weeks of incubation at 12°C.
Data Collection and Processing
The crystals were soaked for cryo-protection and liganding in cryoprotectant solutions,
containing the aimed ligands, for 0.5 to 2 hours prior to flash freezing at 77K using liquid N2. All
cryoprotectant solutions were prepared by enriching the reservoir solution of each crystal with
35% ethylene glycol. The diffraction data was collected at both beamline 6C of the Pohang
Accelerator Laboratory, Pohang, Korea, using the CCD detector Quantum 210 (ADSC) with a
source wavelength of 1.23986 Å or at the Gulf Coast Consortium Protein Crystallography
Beamline (PX1) in the Center for Advanced Microstructures and Devices (CAMD), Louisiana
State University, Baton Rouge, LA., using a Mar 165 mm CCD detector with a source
wavelength of 1.3808 Å. All diffraction data was processed and scaled using HKL2000.
Crystals of hPFKFB2 belong to the primitive orthorhombic space group P212121, having
unit cell dimensions of a = 106.5 Å, b = 113.9 Å, c = 133.2 Å and an asymmetric unit consisting
of two monomers. Crystals of bPFKFB2 belong to the C-centered orthorhombic space group,
C2221, with unit cell dimensions being a = 82.1 Å, b = 169.5 Å, c = 85.3 Å, α =90, β =90, γ =90
and an asymmetric unit consisting of one monomer. Statistics of the reflection data are
summarized in Table 1.
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Table 4.1 Statistics of reflection data and structure refinements. Liganding denotes the states in the
2-Kinase/2-Phosphatase. His-P is phosphorylated at His258. Rsym = Σh(Σj|Ih,j - <Ih>|/ ΣIh,j), where
h=set of Miller indices, j=set of observations of reflection h, and <Ih>=the mean intensity. RMSD
values are deviations from ideal values. Rcrys = Σh || Fo,h | - |Fc,h || / Σh |Fo,h|. Rfree was calculated
using 5% of the complete data set randomly excluded from refinement. The numbers in parentheses
represent values from the highest resolution shell.
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Structure determination and refinement
The structures of hPFKFB2 and bPFKFB2 were determined by molecular replacement
using the Phaser software module implemented in the PHENIX program suite. Initial models for
both orthologues were determined using the human liver PFKFB (1K6M) as a search model (Y.
H. Lee et al. 2003). The final structures were achieved after iterated model rebuilding and
refinement using PHENIX and Coot (P. D. Adams et al. 2010; Emsley and Cowtan 2004). The
Rcrys/Rfree of the final models are 0.202/0.225 and 0.156/0.211 for hPFKFB2 and bPFKFB2,
respectively.
The final models revealed the residues 31-450 out of 505 of hPFKFB2 and those of 28-450
of bPFKFB2. The missing residues are all from both the N- and C- terminal regulatory domains
and are considered disordered, based on the results from mass spectroscopy of melt crystals (data
not shown). For the human model, 93.2% of the 420 revealed residues lie within the ‘most
favorable region’ of the main chain dihedral angle distribution, whereas none are found in the
‘disallowed region’. Similarly, for the 423 residues of the bovine orthologue, 90.9% are within
the “most favorable region” and none are in the “disallowed region”.
4.4 Results and Discussion
Overall Structures of PFKFB2
As summarized in the previous section and Table 1, crystal structures of the two PFKFB2
orthologs were determined ─ human (hPFKFB2) to 2.1Å and bovine (bPFKFB2) to 1.8Å ─ to
elucidate any structural/functional differences in heart-type PFKFB compared to other isoforms.
Similar to the other PFKFB isoforms, the crystal structure of the heart isozyme, for both human
and bovine orthologues, shows a PFKFB-typical head-to-head homodimer arrangement (Figure
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1a) with a dimeric interface constituted primarily through crystal contacts made between two
kinase domains.
Each PFKFB2 monomer consists of a single polypeptide chain that can be subdivided
into four distinct regions: the 6-phosphofructo-2-kinase (2-Kase) domain, the fructose-2,6bisphosphatase (2-Pase) domain, and two regulatory domains. The two catalytic domains are
conserved among the different tissue isoforms with the sequence identity 76-83%, whereas the
N-terminal and C-terminal domains are highly variable. Among 505 amino acid residues of
PFKFB2, residues 1-37 and 451-505 constitute the N- and C- terminal regulatory domains,
whereas residues 38-248 and 249-450 constitute the 2-Kase and 2-Pase domains, respectively.
The sequence identity shared between the human and bovine orthologs is larger than
95%, supporting the notion that the two PFKFB2 orthologs play a physiological role common to
both human and swine. To analyze the structural differences between the two orthologs, Cα
traces of hPFKFB2’s 2-Kase and 2-Pase domains were superimposed, separately, onto
corresponding domains of bPFKFB2 (Figure 1b). It was not appropriate to compare the two
domains together, because differences in liganding states of the two orthologs cause differences
in the domain-domain interface. Supporting the sequence identity, the two catalytic domains
showed a high degree of overall similarity, with RMSD values of 1.46 Å and 0.68 Å, for the 2Kase and 2-Pase domains, respectively. Although the discrepancy in the 2-Kase domains is
higher than expected, no significant structural differences between the two orthologs, which
would implicate coinciding differences in the structure/function relationship, are apparent.
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Figure 4.1. Dimeric arrangement of heart form and a comparison of the structures of the human
and bovine orthologues. (A) Head-to-head homodimer arrangement of the human PFKFB2.
Shown in gray is a complete monomer, while the red and blue colors depict the 2-Kase and 2Pase domains, respectively. Ligands are colored by element and are shown in stick form. (B)
Superimposed C-alpha traces of bovine (white) and human (light gray) kinase and phosphatase
domains. The phosphatase domains contain Fru-6-P from the bovine orthologue in the F-2,6-P2
binding site. The kinase domains with ADP and Citrate from the bovine orthologue in the ATP
and F6P binding sites, respectively.
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The unexpectedly high RMSD for the 2-Kase domains is likely due to differences in
liganding states of the two orthologs despite similar liganding conditions during crystallization.
For both the structures, Fru-6-P and citrate were in common, whereas AMPPNP ─ a nonhydrolyzable ATP analog ─ and ADP were exclusively included fill the ATP pockets of
hPFKFB2 and bPFKFB2, respectively. Structural dissimilarities were concentrated to localized
regions within-or-near the 2-Kase’s active site and correlate with citrate’s binding to the 2-Kase
domain. Despite Fru-6-P being present in crystallization conditions for both orthologues, it
didn’t complex with the 2-kinase domain of either, regardless of concentration. Instead, citrate,
from an earlier purification step, occupies the Fru-6-P binding pocket. Interestingly, the binding
of citrate appears to significantly influence ATP but not ADP binding to the 2-Kase domain. The
details will be discussed in the following sections.
Conserved catalytic binding of ATP and ADP to the 2-Kase domain
Both hPFKFB2 and bPFKFB2 were co-crystallized in the presence of ADP and
AMPPNP, respectively, which were clearly visible within the ATP-binding pocket of the 2-Kase
domain based on |Fo| - |Fc| omit maps. The binding of ADP in bPFKFB2 is analogous to the
catalytic mode of ADP and ATP, which were well characterized and elucidated in previous
studies of the PFKFB protein system (Kim et al. 2007; Y. H. Lee et al. 2003). The adenine
moiety resides in a partly solvent-exposed hydrophobic pocket stabilized primarily through CH-π
contributions made by Gly51, Tyr54, and Val221. A single hydrogen bond is formed between
the adenine N6 and the Oδ of Asn168. The nucleotide diphosphates, on the other hand, occupy a
highly anionic phosphate binding loop created by a Walker A motif ─ conserved as 49

GLPARGKT56- in all PFKFB isoforms (Walker et al. 1982). Additional hydrogen bonds to the

phosphate moieties are contributed from the side chains of Lys172 and Tyr428. This binding is
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well conserved among all PFKFB isoforms. However, Tyr428 plays a different role upon
binding of ATP in the presence of citrate bound to 2-Kase.
Citrate binding to the 2-Kase domain
There was no Fru-6-P molecule bound to the 2-Kinase domain despite being present in
the crystallization mixture, because the 2-Kase, which follows an ordered reaction, requires ATP
binding prior to Fru-6-P binding. Instead, citrate was found to be bound to the Fru-6-P pocket of
the 2-Kase domains of both hPFKFB2 and bPFKFB2 with strong hydrogen bonds to Thr130 and
Tyr197 and salt bridges with Arg78 and Arg102. Except for Arg102, which is conserved though,
all of these residues are known to be involved in the catalytic binding of Fru-6-P to the 2-Kase
domain. This binding mode of citrate is conserved between the bovine and human orthologs. It is
known that the 2-Kase of PFKFB2, the heart isoform, is very sensitive to inhibition from
products of TCA cycle such as succinate and citrate. A previous structural study has suggested
that succinate behaves like a competitive inhibitor against Fru-6-P (Galluzzi et al. 2013).

Figure 4.2. Citrate binding in the 2-Kase domain. (A) Superimposed structures of the citrate binding
pocket for human (blue) and bovine (light gray) orthologues. Residues forming interactions with citrate
are represented as sticks, with a ribbon diagram representing the mainchain. Human PFKFB2 is depicted
as a blue ribbon with sticks containing green carbon atoms. In contrast, bovine PFKFB2 is represented
as a light gray ribbon with sticks containing white carbon atoms. (B) AMPPCP and F6P from PFKFB3
(2DWP) overlaid onto the citrate binding site of human PFKFB2. The distance between the carboxy
arm from citrate and nearest atom from the overlaid AMPPCP is shown. Both AMPPCP and F6P are
semi-transparent colored orange.
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However, citrate bound to PFKFB2 suggests an inhibition pattern, which is different from
that of succinate, which was previously studied (Yuen et al. 1999). While primarily located in the
Fru-6-P binding site, citrate, unlike succinate, impedes the γ-phosphate of AMPPNP from
occupying its normal location for the Fru-2,6-P2 synthesis. When citrate from hPFKFB2 was
superimposed onto a pseudo-Michaelis complex of PFKFB3 (2DWP), one of the three carboxy
group arms of citrate is only 1.2Å
away from the γ-phosphate of
AMPPCP (Kim et al. 2007). Such
close proximity of two negatively
charged acidic groups is both
sterically and electrostatically
unfavorable for ATP binding but
ADP binding is not significantly
influenced. Thus, it has been
suggested that ATP binding to the
2-Kase domain in the known
catalytic mode is not favored in
the presence of citrate. And,
considering perfect conservation
of all the residues for citrate,
binding of citrate to the four
PFKFB isoforms would be very
similar.

Figure 4.3. Ligand Binding within the 2-Kase Domain. (A)
Human PFKFB2 complexed with AMPPNP and Citrate.
Superimposed are AMPPCP and F6P from the pseudo-substrate
complex with PFKFB3 (2DWP), showing the catalytic ATP
and F6P binding modes, respectively. (B) Ribbon diagram view
of human PFKFB2 (blue) super-imposed onto the bovine
orthologue (light gray). The sidechains and their positional
differences are shown for residues involved in AMPPNP
binding.
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An alternative ATP binding mode to the 2-Kase domain caused by citrate binding
Not surprisingly, the binding mode of AMPPNP in the presence of citrate is markedly
different from the conventional mode of catalytic ATP binding, which is required for the Fru2,6-P2 synthesis by the 2-Kase domain and conserved among all PFKFB isoforms. When
AMPPNP from the hPFKFB2•AMPPNP complex was superimposed onto ADP of
bPFKFB2•ADP complex, as can be seen in Figure 3A, the ribose and adenine rings of AMPPNP
are rotated 115° and 180°, respectively, relative to those of ADP. Furthermore, the centroid of
AMPPNP’s adenine ring is 14Å shifted outward from that of ADP. Consequently, few molecular
interactions are shared among the bindings of adenosine moieties of AMPPNP and ADP to
PFKFB2 and, thus, the nucleoside binding sites for AMPPNP are remarkably different from that
of ADP (Figure 3B). From the AMPPNP-complexed structure, it can be seen that the α-carbon of
Pro176 shifts ~3.3Å, placing the residue’s R-group perpendicular to AMPPNP’s planar ring,
allowing for CH-π contributions. More significant contributions come by way of π-π stacking
interactions with the phenol side chain of Tyr428, which is otherwise involved in interaction
with the phosphate moieties. For the π-π stacking between the adenine ring and Tyr428, the βhairpin containing Tyr428 shifted 4Å and the phenol sidechain rotated away from the position
for its conventional interaction with the -phosphate moiety of ADP (Figure 3C).

As a consequence, the γ-phosphate of AMPNP occupies the site for the β-phosphate of
ADP or catalytic ATP, sharing many contact residues with the α- and β- phosphates of ADP
(Figure 3B). Of the five residues forming the Walker A motif, Tyr54 is the only notable absence.
As for sidechain interactions, the phosphate stabilizing hydrogen bond of Tyr428 is replaced by
Ser174. Interactions with Lys172, on the other hand, are completely lost, with the residue
flipping outward towards the solvent. This atypical binding of AMPPNP is inappropriate for the
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2-Kase catalytic reaction and appeared to be caused by the citrate binding to 2-Kase as described
in the following section.
Citrate inhibition at the active site of the 2-Kinase domain
Although previous studies have reported citrate to inhibit PFKFB enzymes, particularly
the heart isotype, the inhibition mechanism has remained unknown (Ros and Schulze 2013).
From the human structure of PFKFB2 presented here, it can now be seen that citrate
competitively blocks F6P binding while simultaneously prohibiting ATP, or any γ-phosphate
containing analogues, from binding in a catalytically active position. Inhibition studies were
conducted to validate these structural observations. Non-linear regression analyses of the data
supported the structural findings, showing citrate to act as a competitive inhibitor for F6P with a
Ki of 80.3±6.54µM and non-competitive inhibitor for ATP with a Kis of 50.23±8.01µM and Kii
of 58.75±9.9µM, as shown in the double-reciprocal plot (Figure 4.4). The mixed inhibition
agrees with the observation that citrate influences but does not completely block ATP from
binding.

Figure 4.4. 2-Kase inhibition by Citrate. (A) Double reciprocal plot with F6P as the variable substrate.
(B) Double reciprocal plot with ATP as the variable substrate.
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Table 4.2. Citrate inhibition properties on wild-type and mutant PFKFB2.

To validate biological significance of the citrate binding and the consequentially altered
binding of ATP, a site-directed mutant, Y428A, the π-π stack provider for the altered ATP
binding mode was mutated to alanine, was prepared and its kinetic properties analyzed in
comparison to the wild-type, as shown in Table 4.2. The Y428A mutant PFKFB2 showed a
kinetic pattern similar to wild-type hPFKFB2, yet exhibited a notable 20-fold increase in affinity
for citrate from 50.2 µM to 2.4 µM. All other kinetic parameters showed a modest increase in
the mutant’s affinity for substrates. Interestingly, the inhibitory effect of citrate was associated
with a near 10-fold increase in Vmax. This difference is likely attributable to a reduction in the
non-catalytic, inhibitory binding of ATP in response to the lost π-π stacking interactions between
phenyl ring and the adenine base of the inhibitory ATP binding.
The apparent differences in kinetic properties between wild-type and the mutant strongly
suggest that Tyr428 makes significant contributions to citrate inhibition of 2-Kase by allowing
ATP to bind in a non-catalytic, inhibitory fashion. As a consequence, citrate is not only an
apparent competitive inhibitor against Fru-6-P but also makes ATP act as an apparent inhibitor.
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The present study suggests that the inhibitory ATP binding significantly depends on Tyr428
mediated - stack interactions between the adenine base moiety of ATP and the tyrosine side
chain. When these - stacking interactions were prevented, as with the Y428A mutant, the
inhibitory binding of ATP was decreased, making the overall inhibition potency of citrate
weaker.
The suggested model is in agreement with the previously accepted model of energy
metabolism within cardiac cells. It has been well established that the heart cells depend mainly
on oxidation of fatty acids and ketone bodies as energy source and that glycolysis is mostly down
regulated in the heart through the so called “glucose-sparing effect”. This suggests a possible
model of the glucose-sparing effect. An unnecessary increase in the myocardial levels of Fru2,6-P2 , the most potent allosteric activator of the glycolysis rate-regulator protein,
phosphofructokinase, is avoided by the citrate-sensitive 2-Kase domain in PFKFB2 isoform.
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CHAPTER 5: CONCLUSIONS
Regulation of glucose metabolism is a vitally important aspect of cell physiology for both
normal and diseased conditions. Many regulatory elements are involved in the process of
regulating glycolytic flux; chief among these are the tissue-specific isozymes of PFKFB.
Responsible for controlling the rate-limiting step of glycolysis, namely the conversion of F6P to
F-1,6-P2 by PFK-1, PFKFB isozymes catalyze both the synthesis and degradation of F-2,6-P2 ─
the most potent allosteric activator of the entire glycolytic pathway. Through the regulation of
cellular concentrations of F-2,6-P2, the PFKFB isozymes exert tremendous influence over
glycolytic flux, and consequently, cellular energy production. It’s not surprising that alterations
in expression levels of the PFKFB isozymes are tied to many diseases; such alterations have
been shown to be a hallmark of virtually all types of cancer, often being required for both
malignant transformation and neoplastic growth.
The inducible isoform, PFKFB3, has been implicated in the enhanced glycolytic activity
observed in cancer cells, otherwise known as the Warburg effect. With a catalytic activity more
than 10-fold higher than any other isoforms, PFKFB3 dramatically increases the concentration of
F-2,6-P2, allowing for 10- to 100-fold increases in glycolytic activity within growing tumors.
This enhanced glycolysis has been reported to be crucial for tumorigenesis, with studies showing
that genetic disruptions of PFKFB3 lead to apoptotic cell death of proliferation cancer cells.
Accordingly, inhibition of this cancer-specific glycolysis has been suggested as a strategy to kill
cancer cells, with PFKFB3 being the primary therapeutic target. Typically, the first step in the
drug development process begins with computational screening, a technique used to reduce the
number of molecules to be physically tested, allowing for faster and cheaper drug development.
However, studies of the efficacy of virtual screening of small molecule kinases, the protein
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family to which PFKFB3 belongs, are sparse, with none exploring the advantages and/or
disadvantages of using tiered approaches. The first study presented in this work addressed this
issue by investigating the efficacy of a pharmacophore screening-combined, structure-based
docking approach on the human inducible PFKFB3 isoform. Five different structure-based
docking programs were evaluated individually, and in conjunction, with a pharmacophore
screening procedure using novel, bioactive compounds for PFKFB3. The study revealed
significant differences in enrichment rates and screening times among single-method docking
programs, with no discernable correlation between computational intensity and enrichment rates;
whereas tiered approaches ─ pharmacophore screening in addition to structure-based docking ─
improved enrichments rates in 80% of cases, reduced CPU costs up to 7-fold, and lessened
enrichment variability among the different structure-based docking methods. These findings are
the first to demonstrate that tiered virtual screening approaches can be successfully applied to
PFKFB3, and by extension small molecule kinases, by showing that such approaches can
increase efficacy, reduce time, and normalize variability relative to structure-based docking
methods alone.
The structural and kinetic characteristics of citrate, a well-known inhibitor of PFKFB
enzymes, were also investigated using the heart isoform, PFKFB2. Citrate serves as an
important negative feed-back mechanism to limit glycolytic activity through the inhibition of
PFKFB enzymes, especially in cardiac cells, however, until now, the structural and mechanistic
details of citrate’s inhibition were wholly unknown. In this work, we established a molecular
basis for citrate’s inhibition through a combination of X-ray crystallography and inhibition
kinetics. Citrate-complexed structures of the human and bovine PFKFB2 orthologues were
solved to resolutions of 2.0 and 1.8Å, respectively. In both structures, citrate was observed to
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fully occupy the binding site of Fructose-6-phosphate (F6P), competitively blocking F6P from
binding, while also extending into the γ-phosphate binding site of ATP. This steric and
electrostatic occlusion of the γ-phosphate binding site was observed to be highly consequential to
the binding mode of the molecule residing in the ATP binding pocket. The bovine structure,
which had ADP co-complexed with citrate, closely resembled other isoforms both in backbone
and side-chain placement, with ADP closely mimicking the catalytic binding mode of ATP. The
human structure, however, had AMPPNP co-complexed with citrate, which, unlike ADP, has a
γ-phosphate. The presence of this γ-phosphate forces the adoption of a non-catalytic binding
mode of AMPPNP in response to occlusion of the γ-phosphate binding site by citrate, prompting
significant conformational changes within the ATP binding pocket of the 2-kinase domain.
Inhibition kinetics were used to validate the structural observations and confirmed citrate’s
inhibition mechanism to be competitive for F6P and mixed for ATP. Prior to this work, no
inhibitor had been identified as having a dual-action inhibition mechanism for PFKFB enzymes.
Elucidation of citrates dual-action inhibition mechanism now enables citrate to be used as a
foundation from which new, more potent inhibitors are able to be developed for PFKFB enzymes
and thus aiding in the development of new therapeutic agents targeting diseases associated with
PFKFB enzymes.
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